IMS Health 10-Q 30 Oct 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 31, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'IMS	'
Entity Registrant Name	'IMS Health Holdings, Inc.	'
Entity Central Index Key	'0001595262	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	333,227,723

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Financial Position (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Current Assets:	'	'
Cash and cash equivalents	$354	$725
Restricted cash	24	27
Accounts receivable, net	318	313
Other current assets	314	262
Total Current Assets	1,010	1,327
Property, plant and equipment, at cost	332	262
Less accumulated depreciation	-177	-145
Property, plant and equipment, net	155	117
Computer software, net	263	263
Goodwill	3,500	3,573
Other identifiable intangibles, net	2,265	2,517
Other assets	197	202
Total Assets	7,390	7,999
Current Liabilities:	'	'
Accounts payable	95	103
Accrued and other current liabilities	475	583
Current portion of long-term debt	51	66
Deferred revenues	190	180
Total Current Liabilities	811	932
Postretirement and postemployment benefits	75	77
Long-term debt	3,848	4,894
Deferred tax liability	947	1,102
Other liabilities	73	111
Total Liabilities	5,754	7,116
Commitments and Contingencies (Note 11)	'	'
Shareholders’ Equity:	'	'
Common Stock, $0.01 par value, 700.0 and 307.5 shares authorized, 332.9 and 280.5 shares issued at September 30, 2014 and December 31, 2013, respectively	3	3
Capital in excess of par	1,952	913
Accumulated deficit	-217	-20
Treasury stock, at cost, 0.8 and 0.5 shares at September 30, 2014 and December 31, 2013, respectively	-10	-6
Accumulated other comprehensive loss	-92	-7
Total Shareholders’ Equity	1,636	883
Total Liabilities and Shareholders’ Equity	$7,390	$7,999

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Financial Position (Parenthetical) (USD $)	Sep. 30, 2014	Mar. 24, 2014	Dec. 31, 2013
In Millions, except Per Share data, unless otherwise specified
Statement Of Financial Position [Abstract]	'	'	'
Common stock, par value	$0.01	$0.00	$0.01
Common Stock, shares authorized	700	'	307.5
Common Stock, shares issued	332.9	'	280.5
Treasury stock, shares	0.8	'	0.5

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Comprehensive (Loss) Income (USD $)	3 Months Ended		9 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]	'	'	'	'
Revenue	$656	$633	$1,963	$1,870
Information	382	381	1,149	1,138
Technology services	274	252	814	732
Operating costs of information, exclusive of depreciation and amortization	164	163	502	480
Direct and incremental costs of technology services, exclusive of depreciation and amortization	147	130	423	377
Selling and administrative expenses, exclusive of depreciation and amortization	139	143	557	433
Depreciation and amortization	109	98	331	303
Severance, impairment and other charges	4	-1	29	1
Operating Income	93	100	121	276
Interest income	1	1	3	3
Interest expense	-43	-87	-181	-241
Other income (loss), net	7	-54	-281	-44
Non-Operating Loss, Net	-35	-140	-459	-282
Income (loss) before income taxes	58	-40	-338	-6
(Provision for) benefit from income taxes	-11	20	141	6
Net Income (Loss)	47	-20	-197	'
Earnings (Loss) per Share Attributable to Common Shareholders:	'	'	'	'
Basic	$0.14	($0.07)	($0.63)	'
Diluted	$0.14	($0.07)	($0.63)	'
Weighted-Average Common Shares Outstanding:	'	'	'	'
Basic	332.1	280	314.1	280
Diluted	342.3	280	314.1	280
Other Comprehensive (Loss) Income:	'	'	'	'
Net Income (Loss)	47	-20	-197	'
Cumulative translation adjustment (net of taxes of $(26) and $(12), for the three months ended and $(36) and $10 for the nine months ended, respectively)	-115	49	-78	-150
Unrealized gains (losses) on derivatives (net of taxes of $(5) and $2 for the three months ended and $(4) and $(3) for the nine months ended, respectively)	7	-3	-8	6
Losses (gains) on derivative instruments, reclassified into earnings (net of taxes of $— and $2 for the three months ended and $— and $4 for the nine months ended, respectively)	1	-3	1	-7
Postretirement and postemployment adjustments (net of taxes)	'	1	'	1
Other Comprehensive (Loss) Income	-107	44	-85	-150
Total Comprehensive (Loss) Income	($60)	$24	($282)	($150)

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Comprehensive (Loss) Income (Parenthetical) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]	'	'	'	'
Cumulative translation adjustment, taxes	($26)	($12)	($36)	$10
Unrealized (losses) gains on derivatives, taxes	-5	2	-4	-3
Gains on derivative instruments, reclassified into earnings, taxes	'	$2	'	$4

Condensed_Consolidated_Stateme4

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash Flows from Operating Activities:	'	'
Net loss	($197)	'
Adjustments to Reconcile Net Loss to Net Cash (Used in) Provided by Operating Activities:	'	'
Depreciation and amortization	331	303
Losses on extinguishment of debt	79	9
Deferred income taxes	-197	-48
Non-cash stock-based compensation charges	52	18
Foreign exchange loss on revaluation of foreign denominated debt	'	22
Non-cash losses (gains) on derivative instruments	6	-8
Non-cash amortization of debt original issue discount and debt issuance costs	15	27
Losses on Venezuela remeasurement	49	14
Other	1	4
Change in assets and liabilities, excluding effects from acquisitions and dispositions:	'	'
Net (increase) decrease in accounts receivable	-1	20
Net (increase) decrease in other current assets	-32	6
Net decrease in accounts payable	-10	-12
Net decrease in accrued and other current liabilities	-100	-5
Net increase in deferred revenues	6	7
Increase in pension assets (net of liabilities)	-12	-8
Increase in other long-term assets (net of long-term liabilities)	-27	-13
Net Cash (Used in) Provided by Operating Activities	-37	336
Cash Flows from Investing Activities:	'	'
Capital expenditures	-59	-25
Additions to computer software	-70	-53
Purchases of short-term investments	'	-23
Payments for acquisitions of businesses, net of cash acquired	-58	-74
Purchase of interest rate caps	-21	'
Other investing activities, net	1	1
Net Cash Used in Investing Activities	-207	-174
Cash Flows from Financing Activities:	'	'
Borrowings under revolving credit facility	579	135
Repayments of revolving credit facility	-307	-135
Repayments of debt	-1,770	-25
Proceeds from issuance of debt	499	750
Debt issuance costs and amendment fees	-22	-17
Contingent consideration payment	-28	-3
Dividends paid	'	-753
Proceeds from initial public offering, net of costs	987	'
Other financing activities	-3	'
Net Cash Used in Financing Activities	-65	-48
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-62	-31
(Decrease) Increase in Cash and Cash Equivalents	-371	83
Cash and Cash Equivalents, Beginning of Period	725	580
Cash and Cash Equivalents, End of Period	$354	$663

Condensed_Consolidated_Stateme5

Condensed Consolidated Statements of Shareholders' Equity (USD $)	Total	Common Stock	Treasury Stock	Capital in Excess of Par	Accumulated Deficit	Cumulative Translation Adjustment	Unamortized Postretirement & Postemployment Adjustment	Unrealized (Losses) Gains on Derivative Instruments	Losses (Gains) on Derivative Instruments Reclassified into Earnings	Accumulated Other Comprehensive Income (Loss)
In Millions
Balance at Dec. 31, 2012	$1,683	$3	($4)	$1,634	($102)	$192	($41)	($8)	$9	$152
Balance, treasury shares at Dec. 31, 2012	'	'	0.4	'	'	'	'	'	'	'
Balance, common shares at Dec. 31, 2012	'	280.4	'	'	'	'	'	'	'	'
Net Income (Loss)	82	'	'	'	82	'	'	'	'	'
Issuances under stock plans and management investments	2	'	'	2	'	'	'	'	'	'
Issuances under stock plans and management investments, Shares	'	0.1	'	'	'	'	'	'	'	'
Repurchases of common stock	-2	'	-2	'	'	'	'	'	'	'
Repurchases of common stock, Shares	'	'	0.1	'	'	'	'	'	'	'
Stock-based compensation expense	22	'	'	22	'	'	'	'	'	'
Dividends paid to shareholders, net of tax	-745	'	'	-745	'	'	'	'	'	'
Cumulative translation adjustments, net of tax	-183	'	'	'	'	-183	'	'	'	-183
Postretirement & postemployment adjustments, net of tax	24	'	'	'	'	'	24	'	'	24
Unrealized gains (losses) on derivative instruments, net of tax	9	'	'	'	'	'	'	9	'	9
Losses (Gains) on derivative instruments reclassified into earnings, net of tax	-9	'	'	'	'	'	'	'	-9	-9
Balance at Dec. 31, 2013	883	3	-6	913	-20	9	-17	1	'	-7
Balance, treasury shares at Dec. 31, 2013	0.5	'	0.5	'	'	'	'	'	'	'
Balance, common shares at Dec. 31, 2013	280.5	280.5	'	'	'	'	'	'	'	'
Net Income (Loss)	-197	'	'	'	-197	'	'	'	'	'
Issuances of common stock	987	'	'	987	'	'	'	'	'	'
Issuances of common stock, Shares	'	52.4	'	'	'	'	'	'	'	'
Repurchases of common stock	-4	'	-4	'	'	'	'	'	'	'
Repurchases of common stock, Shares	'	'	0.3	'	'	'	'	'	'	'
Stock-based compensation expense	52	'	'	52	'	'	'	'	'	'
Cumulative translation adjustments, net of tax	-78	'	'	'	'	-78	'	'	'	-78
Unrealized gains (losses) on derivative instruments, net of tax	-8	'	'	'	'	'	'	-8	'	-8
Losses (Gains) on derivative instruments reclassified into earnings, net of tax	1	'	'	'	'	'	'	'	1	1
Balance at Sep. 30, 2014	$1,636	$3	($10)	$1,952	($217)	($69)	($17)	($7)	$1	($92)
Balance, treasury shares at Sep. 30, 2014	0.8	'	0.8	'	'	'	'	'	'	'
Balance, common shares at Sep. 30, 2014	332.9	332.9	'	'	'	'	'	'	'	'

Basis_of_Presentation_and_Rece

Basis of Presentation and Recently Issued Accounting Standards	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation and Recently Issued Accounting Standards	'
	Note 1. Basis of Presentation and Recently Issued Accounting Standards
	Background
	IMS Health Holdings, Inc. (the “Company”) is a leading global information and technology services company providing clients in the healthcare industry with comprehensive solutions to measure and improve their performance. The Company has one of the largest and most comprehensive collections of healthcare information in the world, spanning sales, prescription and promotional data, medical claims, electronic medical records and social media. The Company standardizes, organizes, structures and integrates this data by applying its sophisticated analytics and leveraging its global technology infrastructure to help its clients run their organizations more efficiently and make better decisions to improve their operational and financial performance. The Company has a presence in over 100 countries and generated 63% of its 2013 revenue from outside the United States.
	The Company serves key healthcare organizations and decision makers around the world, spanning the breadth of life science companies, including pharmaceutical, biotechnology, consumer health and medical device manufacturers, as well as distributors, providers, payers, government agencies, policymakers, researchers and the financial community. The Company’s information and technology services offerings, which it has developed with significant investment over its 60-year history, are deeply integrated into its clients’ workflow.
	On February 26, 2010, the Company was acquired by affiliates of TPG Global, LLC (together with its affiliates, “TPG”), CPP Investment Board Private Holdings, Inc. (“CPPIB-PHI”), a wholly owned subsidiary of the Canada Pension Plan Investment Board (together with its affiliates, “CPPIB”), and Leonard Green & Partners, L.P. (“LGP” and collectively with TPG and CPPIB, the “Sponsors”) in an all-cash transaction.
	Initial Public Offering
	On April 4, 2014, the Company’s common stock began trading on the New York Stock Exchange under the symbol “IMS”. On April 9, 2014, the Company completed its Initial Public Offering (“IPO”) of its common stock at a price to the public of $20.00 per share. The Company issued and sold 52 million shares of common stock in the IPO. The selling shareholders offered and sold 22.75 million shares of common stock in the IPO, including 9.75 million shares that were offered and sold by the selling shareholders pursuant to the full exercise of the underwriters’ allotment to purchase additional shares. As of September 30, 2014, the Sponsors collectively remained the majority shareholders of the Company. The Company raised net proceeds of approximately $987 million from the IPO, after deducting underwriting discounts, commissions and related expenses totaling $53 million. The Company did not receive any of the proceeds from the sale of the shares sold by the selling shareholders.
	Substantially all of the Company’s net proceeds of the IPO, approximately $500 million of borrowings under new term loans, $140 million of borrowings under the revolving credit facility and approximately $400 million of cash on the balance sheet were used to (i) fund the redemption of the Company’s 12.5% Senior Notes and Senior PIK Notes (defined in Note 6 below) and pay related fees and expenses, (ii) pay $30 million in the aggregate to holders of outstanding cash settled stock appreciation rights (“Phantom SARs”) granted under the Company’s 2010 Equity Incentive Plan (the “2010 Equity Plan”) and (iii) pay a one-time fee of $72 million to terminate the management services agreement with the Sponsors.
	Basis of Presentation
	The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. The Condensed Consolidated Financial Statements do not include all the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, all of which are of a normal recurring nature, considered necessary for a fair statement of financial position, results of operations and comprehensive loss, cash flows and shareholders’ equity for the periods presented have been included. The results of operations for interim periods are not necessarily indicative of the results expected for the full year. The December 31, 2013 Condensed Consolidated Statement of Financial Position was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The Condensed Consolidated Financial Statements and related notes should be read in conjunction with the audited Consolidated Financial Statements and related notes of IMS Health Holdings, Inc. included in the Company’s prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, with the Securities and Exchange Commission (the “SEC”) on April 4, 2014 (the “Prospectus”). Certain prior year amounts have been reclassified to conform to the 2014 presentation. Amounts presented in the Condensed Consolidated Financial Statements may not add due to rounding.
	Recently Issued Accounting Standards
	In August 2014, the Financial Accounting Standards Board (“FASB”) issued guidance on management’s responsibility to assess an entity’s ability to continue as a going concern and provide related footnote disclosures in certain circumstances.  The guidance is effective for the Company’s interim and annual periods beginning after December 15, 2016.  The Company does not believe the adoption of this guidance will impact its consolidated financial statements or disclosures.
	In June 2014, the FASB issued guidance on accounting for share-based payments that a performance target that affects vesting and could be achieved after the requisite service period be treated as a performance condition. The guidance is effective for the Company’s interim and annual periods beginning January 1, 2016. The Company does not believe the adoption of this guidance will have a material impact to its consolidated financial statements.
	In May 2014, the FASB issued revised guidance on the recognition of revenue from contracts with customers. The guidance provides that revenue should be recognized for the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires enhanced disclosures and is effective for the Company’s interim and annual periods beginning January 1, 2017. The Company is currently evaluating this guidance to determine any potential impact that it may have on its financial results.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Acquisitions	'
	Note 2. Acquisitions
	The Company makes acquisitions in order to expand its products, services and geographic reach. During the three months ended September 30, 2014, the Company completed the acquisitions of Aileron Solutions, LLC (U.S.), Global Channel Marketing Solutions (U.S.) and additional consumer health businesses of Nielsen Holdings N.V. in certain European markets. Aileron uses anonymous medical claims data to provide analytic services to pharmaceutical, biotechnology, and medical device companies for the purpose of identifying healthcare professionals that will most benefit from information regarding medical device, diagnostics, or prescription products. This acquisition accelerates the Company’s services in two primary growth areas: oncology specialty and the medical device and diagnostic channel. Global Channel Marketing Solutions is a multi-channel marketing company that helps life sciences companies transform their customer engagements through multi-channel marketing operations support and solutions. Additionally, during the first six months of 2014, the Company completed the acquisitions of Forcea NV, a Belgium-based company that specializes in business intelligence applications and analytics for hospitals and life sciences organizations, the consumer health business of Nielsen Holdings N.V. in certain other European markets and Kent Capital in the U.S. The total cost for these acquisitions was approximately $60 million, of which $56 million was paid during the nine months ended September 30, 2014 and the balance will be paid in 2015 subject to certain conditions. Acquisition-related costs related to these acquisitions were $2 million and $3 million for the three and nine months ended September 30, 2014, respectively, and were expensed as incurred and recorded in Selling and administrative expense, exclusive of depreciation and amortization. These business combinations were accounted for under the acquisition method of accounting, and as such, the aggregate purchase prices were allocated on a preliminary basis to the assets acquired and liabilities assumed based on estimated fair values as of the closing dates. The purchase price allocation will be finalized after the completion of the valuation of certain intangible assets and any adjustments to the preliminary purchase price allocation are not expected to have a material impact on the Company’s results of operations. The Condensed Consolidated Financial Statements include the results of the acquisitions subsequent to their closing. Had these acquisitions occurred as of the beginning of 2013, the impact on the Company’s results of operations would not have been material. In connection with these acquisitions, the Company recorded goodwill of approximately $31 million, of which $18 million is deductible for tax purposes, computer software of $2 million (weighted-average amortization period of 5 years) and intangible assets of approximately $29 million during the nine months ended September 30, 2014. The intangible assets acquired were comprised of client relationships and other of $24 million (weighted-average amortization period of 7.2 years) and databases of $5 million (weighted-average amortization period of 3 years).
	During the nine months ended September 30, 2014, the Company recorded measurement period adjustments related to acquisitions that occurred in 2013. These adjustments did not have a material impact on the Company’s Condensed Consolidated Financial Statements for any period reported, and therefore, the Company did not retrospectively adjust the Condensed Consolidated Statement of Financial Position as of December 31, 2013.
	Contingent consideration
	Under the terms of certain acquisition-related purchase agreements, the Company may be required to pay additional amounts as contingent consideration based on the achievement of certain financial performance related metrics, ranging from $0 to $25 million through 2017. The Company’s contingent consideration recorded on the balance sheet was approximately $25 million and $65 million at September 30, 2014 and December 31, 2013, respectively. The fair value measurement of this contingent consideration is classified within Level 3 of the fair value hierarchy (see Note 5) and reflects the Company’s own assumptions in measuring fair values using the income approach. In developing these estimates, the Company considered certain performance projections, historical results, and industry trends.

Goodwill_and_Identifiable_Inta

Goodwill and Identifiable Intangible Assets	9 Months Ended
	Sep. 30, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill and Identifiable Intangible Assets	'
	Note 3. Goodwill and Identifiable Intangible Assets
	The following table sets forth changes in the Company’s goodwill for the nine months ended September 30, 2014.
	(in millions)	Goodwill
	Balance at December 31, 2013	$	3,573
	Goodwill assigned in purchase price allocations (see Note 2)		31
	Foreign currency translation adjustments and other		(104	)
	Balance at September 30, 2014	$	3,500
	The gross carrying amounts, related accumulated amortization and the weighted average amortization periods of the Company’s intangible assets are listed in the following table:
		30-Sep-14								December 31, 2013
	(in millions)	Gross			Accumulated			Weighted Average		Gross		Accumulated
		Carrying			Amortization			Amortization		Carrying		Amortization
		Amount						Period (Years)		Amount
	Databases	$	696		$	(628	)		0.5	$	725	$	(549	)
	Client Relationships and other		2,132			(580	)		14		2,152		(491	)
	Trade Names (Finite-Lived)		145			(37	)		14.1		151		(31	)
	Trade Names (Indefinite-Lived)		537			—			N/A		560		—
	Total Intangible Assets	$	3,510		$	(1,245	)		10.8	$	3,588	$	(1,071	)
	Intangible asset amortization expense was $73 million and $71 million during the three months ended September 30, 2014 and 2013, respectively, and $220 million and $214 million for the nine months ended September 30, 2014 and 2013, respectively. Based on current estimated useful lives, amortization expense associated with intangible assets at September 30, 2014 is estimated to be as follows:
	(in millions)	Amortization
	Year ended December 31,	Expense
	Remainder of 2014	$	71
	2015		176
	2016		149
	2017		136
	2018		133
	Thereafter		1,063

Severance_Impairment_and_Other

Severance, Impairment and Other Charges	9 Months Ended
	Sep. 30, 2014
Restructuring And Related Activities [Abstract]	'
Severance, Impairment and Other Charges	'
	Note 4. Severance, Impairment and Other Charges
	As a result of ongoing cost reduction efforts, the Company recorded severance charges consisting of global workforce reductions to streamline its organization. The following table sets forth the activity in the Company’s severance-related reserves for the nine months ended September 30, 2014:
	(in millions)		2014 Plan(1)			2013 Plan(2)			2012 Plan(3)
	Balance at December 31, 2013		$	—		$	12		$	6
	Charges			19			—			—
	Cash payments			(7	)		(4	)		(3	)
	Balance at September 30, 2014		$	12		$	8		$	3
	(1)	In May 2014, the Company implemented a restructuring plan (the “2014 Plan”) and recorded a pre-tax severance charge of $15 million. In September 2014, the Company recorded an additional pre-tax severance charge of $4 million under the 2014 Plan.  The Company expects that cash outlays related to the 2014 Plan will be substantially complete by the end of 2015.
	(2)	In December 2013, the Company implemented a restructuring plan (the “2013 Plan”) and recorded a pre-tax severance charge of $12 million. The Company expects that cash outlays related to the 2013 Plan will be substantially complete by the end of 2015.
	(3)	In December 2012, the Company implemented a restructuring plan (the “2012 Plan”) and recorded a pre-tax severance charge of $23 million. In the third quarter of 2013, $6 million of severance accruals were reversed due to the favorable settlement of required termination benefits and strategic business changes. The Company expects that cash outlays related to the 2012 Plan will be substantially complete by the end of 2014.
	Other charges
	During the nine months ended September 30, 2014, the Company recorded impairment charges of $10 million, $7 million of which related to impaired leases for properties in the U.S. and $3 million for the write-down of certain assets and contract-related charges for which the Company will not realize any future economic benefits.
	During the three and nine months ended September 30, 2013, the Company recorded impairment charges of $6 million and $7 million, respectively, related to impaired leases for properties vacated in the U.S. and contract-related charges for which the Company will not realize any future economic benefits.

Derivatives_and_Fair_Value

Derivatives and Fair Value	9 Months Ended
	Sep. 30, 2014
Derivatives And Fair Value Disclosure [Abstract]	'
Derivatives and Fair Value	'
	Note 5. Derivatives and Fair Value
	Foreign exchange risk management
	The Company transacts business in more than 100 countries and is subject to risks associated with changing foreign exchange rates. The Company’s objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes. Accordingly, the Company enters into foreign currency forward contracts to minimize the impact of foreign exchange movements on non–functional currency assets and liabilities and to hedge non-U.S. Dollar anticipated royalties (“Royalty Hedging”). Additionally, through March 2014, the Company utilized foreign currency forward contracts to minimize the impact of foreign exchange movements on EBITDA. These contracts will unwind through the end of 2014. It is the Company’s policy to enter into foreign currency transactions only to the extent necessary to meet its objectives as stated above. The Company does not enter into foreign currency transactions for investment or speculative purposes. The principal currencies hedged are the Euro, the Japanese Yen, the Swiss Franc and the Canadian Dollar.
	The forward contracts entered into for balance sheet risk management purposes are not designated as hedges and are carried at fair value, with changes in the fair value recorded to Other income (loss), net in the Condensed Consolidated Statements of Comprehensive (Loss) Income. These contracts do not subject the Company to material balance sheet risk because gains and losses on these derivatives are intended to offset gains and losses on the assets and liabilities being hedged.
	Unrealized and realized gains and losses on the contracts entered into for managing foreign exchange movement on EBITDA did not qualify for hedge accounting, and therefore were not deferred and were included in the Condensed Consolidated Statements of Comprehensive (Loss) Income in Other income (loss), net.
	The forward contracts entered into for Royalty Hedging purposes are designated as hedges and are carried at fair value, with changes in the fair value recorded to Accumulated Other Comprehensive Income (Loss) (“AOCI”). The change in fair value is reclassified from AOCI to earnings in the quarter in which the hedged royalty is paid.
	For derivatives designated as hedges, the Company assesses, both at the inception of the hedge and on an ongoing basis, whether the derivatives are highly effective in offsetting changes in fair values or cash flows of hedged items. If it is determined that a derivative ceases to be highly effective as a hedge, the Company will discontinue hedge accounting with respect to that derivative prospectively. When it is probable that a hedged forecasted transaction will not occur, the Company discontinues hedge accounting for the affected portion of the forecasted transaction, and reclassifies gains or losses that were accumulated in AOCI to earnings in Other income (loss), net on the Condensed Consolidated Statements of Comprehensive (Loss) Income. Cash flows are classified consistent with the underlying hedged item.
	In April 2014, the Company designated Euro currency borrowings as hedges of its foreign currency exposures of the net investment in certain foreign affiliates. As of September 30, 2014, these borrowings (net of original issue discount) were €869 million ($1,093 million). The effective portion of foreign exchange gains or losses on the remeasurement of the debt is recognized in the cumulative translation adjustment component of AOCI with the related offset in long-term debt. Those amounts would be reclassified from AOCI to earnings upon the sale or substantial liquidation of these net investments. The amount of foreign exchange gains related to the net investment hedges included in cumulative translation adjustment for the three and nine months ended September 30, 2014 was $94 million and $105 million, respectively.
	The following table details the components of foreign exchange gain (loss) included in Other income (loss), net on the Condensed Consolidated Statements of Comprehensive (Loss) Income:
			Three Months Ended						Nine Months Ended
			September 30,						September 30,
	(in millions)		2014			2013			2014				2013
	Translation of non-functional currency debt		$	—		$	(34	)	$	—			$	(22	)
	Revaluation of other non-functional currency assets and liabilities(1)			8			(17	)		(48	)			(14	)
	Effect of derivatives			(4	)		—			(4	)			7
	Total foreign exchange gain (loss)		$	4		$	(51	)	$	(52	)		$	(29	)
	-1	The nine months ended September 30, 2014 included a $49 million charge related to a change in the exchange rate used to remeasure the Company’s Venezuelan Bolívar account balances. Additionally, the nine months ended September 30, 2013 included a $14 million charge resulting from devaluation of Venezuelan Bolívars. Both the 2014 and 2013 charges are further described below in this Note.
	The foreign exchange forward contracts outstanding designated as hedges have various expiration dates through September 2015. The foreign exchange forward contracts outstanding not designated as hedges have various expiration dates through December 2014. Foreign exchange forward contracts are recorded at estimated fair value. The estimated fair values of the forward contracts are based on quoted market prices.
	Interest rate risk management
	The Company purchases interest rate caps and entered into interest rate swap agreements for purposes of managing its risk in interest rate fluctuations.
	In April 2014, the Company purchased U.S. Dollar denominated interest rate caps (“2014 Caps”) for a total notional value of $1 billion at strike rates ranging between 2% and 3%. These caps are effective at various times between April 2014 and April 2016, and expire at various times between April 2017 and April 2019. The total premiums paid were $21 million. The 2014 Caps are designated as cash flow hedges. The 2014 Caps are in addition to the U.S. Dollar and Euro denominated interest rate caps that the Company purchased in May 2010 (“2010 Caps”). The 2010 Caps have strike rates of 4% and expire at various times through January 2015. The 2010 Caps are not designated as cash flow hedges.
	The Company also entered into U.S. Dollar and Euro denominated interest rate swap agreements in April 2014 (“2014 Swaps”) to hedge interest rate exposure on notional amounts of approximately $600 million of its borrowings. The 2014 swaps were effective between April and June 2014, and expire at various times from March 2017 through March 2021. On these agreements, the Company pays a fixed rate ranging from 1.4% to 2.1% and receives a variable rate of interest equal to the greater of three-month U.S. Dollar London Interbank Offered Rate (“LIBOR”) or three-month Euro Interbank Offered Rate (“EURIBOR”), and 1%. The 2014 Swaps are designated as cash flow hedges. The Company also entered into interest rate swap agreements in May 2010 (“2010 Swaps”) to hedge interest rate exposure on notional amounts of $375 million of its borrowings. The 2010 Swaps were effective January 2012, and expire at various times through January 2016. On these agreements, the Company pays a fixed rate ranging from 3% to 3.3% and receives a variable rate of interest equal to the three-month LIBOR. The 2010 Swaps are not designated as cash flow hedges.
	The fair values of derivative instruments in the Condensed Consolidated Statements of Financial Position are as follows:
						30-Sep-14											31-Dec-13
						Fair Value of Derivative							U.S. Dollar				Fair Value of Derivative				U.S. Dollar
	(in millions)				Balance Sheet Caption	Asset			Liability				Notional				Asset		Liability		Notional
	Derivatives designated as hedging instruments
	Foreign exchange contracts				Accounts receivable/Accounts payable	$	13		$	—			$	215			$	6	$	4	$	202
	Interest rate caps				Non-Current Assets		16			—				1,000				—		—		—
	Interest rate swaps				See below(1)		—			10				565				—		—		—
	Derivatives not designated as hedging instruments
	Foreign exchange contracts				Accounts receivable/Accounts payable		4			7				228				3		11		219
	Interest rate caps				—		—			—				110				—		—		365
	Interest rate swaps				See below(1)		—			6				225				—		12		375
	Total derivatives					$	33		$	23							$	9	$	27
	-1	$2 million included in Accrued and other current liabilities and $14 million included in Other liabilities at September 30, 2014 and $12 million included in Other liabilities at December 31, 2013 in the Condensed Consolidated Statements of Financial Position.
	The effects of derivative instruments on the Condensed Consolidated Statements of Comprehensive (Loss) Income are as follows:
	(in millions)		Effect of Derivatives on Financial Performance
	Derivatives in Cash Flow Hedging Relationships		Amount of Income/(Loss)						Location of Income/(Loss)		Amount of
			Recognized in AOCI						Reclassified from AOCI into		Income/(Loss)
									Earnings		Reclassified from
											AOCI
											into Earnings
	Three Months Ended September 30,		2014			2013					2014				2013
	Foreign exchange contracts		$	15		$	(5	)	Other income (loss), net		$	1			$	4
	Interest rate derivatives			(3	)		—		Interest expense			(2	)			—
	Nine Months Ended September 30,			2014			2013					2014				2013
	Foreign exchange contracts		$	12		$	9		Other income (loss), net		$	1			$	11
	Interest rate derivatives			(16	)		—		Interest expense			(2	)			—
	The pre-tax gain (loss) recognized in earnings on derivatives not designated as hedging instruments was as follows:
			Three Months Ended						Nine Months Ended
			September 30,						September 30,
	(in millions)		2014			2013			2014				2013
	Foreign exchange contracts(1)		$	(5	)	$	(4	)	$	(5	)		$	(4	)
	Interest rate derivatives(2)			—			2			—				7
	Total derivatives not designated as hedging instruments		$	(5	)	$	(2	)	$	(5	)		$	3
	-1	Included in Other income (loss), net
	-2	Included in interest expense
	Changes in the fair value of derivatives that are designated as cash flow hedges are recorded in AOCI to the extent effective and reclassified into earnings in the same period or periods during which the transaction hedged by that derivative also affects earnings. The Company expects $17 million of pre-tax unrealized losses related to its foreign exchange contracts and interest rate derivatives included in AOCI at September 30, 2014 to be reclassified into earnings within the next twelve months.
	Fair value disclosures
	The Company is subject to authoritative guidance which requires a three-level hierarchy for disclosure of fair value measurements as follows:
	Level 1 —	Quoted prices in active markets for identical assets or liabilities.
	Level 2 —	Quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets; and model-derived valuations in which all significant inputs are observable in active markets.
Level 3 —	Unobservable inputs reflecting management’s own assumptions about the inputs used in pricing the asset or liability.
The carrying values of cash, cash equivalents, restricted cash, accounts receivable and accounts payable approximated their fair values at September 30, 2014 and December 31, 2013 due to the short-term nature of these instruments. At September 30, 2014 and December 31, 2013, the fair value of total debt approximated $3,910 million and $5,280 million, respectively, as determined under Level 2 measurements based on quoted prices for these financial instruments.
Recurring measurements
The following tables summarize assets and liabilities measured at fair value on a recurring basis at the dates indicated:
		Basis of Fair Value Measurements
		30-Sep-14
(in millions)		Level 1			Level 2			Level 3				Total
Assets
Short-term investments		$	—		$	1		$	—			$	1
Derivatives			—			33			—				33
Total		$	—		$	34		$	—			$	34
Liabilities
Contingent consideration		$	—		$	—		$	25			$	25
Derivatives			—			23			—				23
Total		$	—		$	23		$	25			$	48
		December 31, 2013
(in millions)		Level 1			Level 2			Level 3				Total
Assets
Short-term investments		$	—		$	4		$	—			$	4
Derivatives			—			9			—				9
Total		$	—		$	13		$	—			$	13
Liabilities
Contingent consideration		$	—		$	—		$	65			$	65
Derivatives			—			27			—				27
Total		$	—		$	27		$	65			$	92
Short-term investments consist of government bond funds. Derivatives consist of foreign exchange contracts and interest rate caps and swaps. The fair value of foreign exchange contracts is based on observable market inputs of spot and forward rates. The fair value of the interest rate caps and swaps is the estimated amount that the Company would receive or pay to terminate such agreements, taking into account market interest rates and the remaining time to maturities.
The following table summarizes Level 3 acquisition-related contingent consideration liabilities (see Note 2) carried at fair value on a recurring basis with the use of unobservable inputs for the period indicated.
(in millions)		Contingent
		Consideration
		Liabilities
Balance at December 31, 2013		$	65
New acquisitions			3
Cash payments			(28	)
Changes in fair value estimates included in Selling and administrative expenses			(15	)
Balance at September 30, 2014		$	25
During the third quarter of 2014, the Company paid $25 million as a final settlement for an earn-out related to a 2013 acquisition.  The settlement resulted in a $9 million change in the fair value of the contingent consideration liability.
Non-recurring measurements
During the second quarter of 2014, the Company recorded a $7 million impairment charge for a leased facility, resulting in a fair value measurement of $9 million at June 30, 2014. The fair value was based on a third party market assessment, a Level 2 measurement. Additionally during the second quarter of 2014, the Company wrote off the value of computer software that was no longer in use to zero and recorded an impairment charge of $2 million. The fair value reflects an internal review of the net realizable value of the software and thus is a Level 3 measurement.
Devaluation of Venezuelan Bolívars
In February 2013, the Venezuelan government announced the devaluation of its currency. The official exchange rate was adjusted from 4.30 Bolívars to each U.S. Dollar to 6.30. The Company’s Swiss operating subsidiary, IMS AG, maintains certain account balances in Bolívars (mainly cash and cash equivalents). As these balances are held in a non-functional currency of IMS AG, the Company is required to mark-to-market these balances at each reporting date and reflect these movements as gains or losses in income. Additionally, since January 2010, Venezuela has been designated as hyper-inflationary, and as such, all foreign currency fluctuations are recorded in income for certain account balances at the Company’s local Venezuelan operating subsidiary. The Company recorded a pre-tax charge of approximately $14 million to Other income (loss), net, in the first quarter of 2013 related to the remeasurement of the IMS AG Venezuelan Bolívar account balances and the remeasurement of certain local Bolívar account balances.
In 2014, the Venezuelan government significantly expanded the use of the Supplementary Foreign Currency Administration System (“SICAD”) I exchange market and created a third exchange market called SICAD II. These markets have exchange rates significantly less favorable than the official exchange rate. As a result, the Company assessed its legal eligibility to access the available foreign exchange mechanisms, the transactions that would be eligible, and the Company’s past and expected future ability to transact through those mechanisms. Based on the Company’s analysis, the Company believes SICAD II represents the rate which best reflects the economics of the Company’s Venezuelan business activity, and as such, the Company concluded that it should utilize the SICAD II exchange rate to remeasure its Venezuelan Bolívar account balances as of June 30, 2014. The SICAD II rate at June 30, 2014 was approximately 50 Bolívars to one U.S. Dollar. As a result of the change to the SICAD II rate, the Company recorded a pre-tax charge of $49 million to foreign exchange loss within Other income (loss), net in the second quarter of 2014. The Company continued to remeasure its Venezuela account balances at the SICAD II rate of approximately 50 Bolívars to one U.S. Dollar as of September 30, 2014. The net assets held and revenue generated by our Venezuelan subsidiaries were not material to our consolidated results as of September 30, 2014.

Debt

Debt	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Debt	'
	Note 6. Debt
	The following table summarizes the Company’s debt at the dates indicated:
	(in millions)	September 30,			December 31,
		2014			2013
	Senior Secured Credit Facilities:
	Senior Secured Term A Loan due 2019—USD LIBOR at average floating rates of 2.48%	$	311		$	—
	Senior Secured Term A Loan due 2019—EUR LIBOR at average floating rates of 2.31%		166			—
	Senior Secured Term B Loan due 2021—USD LIBOR at average floating rates of 3.50%		1,739			1,747
	Senior Secured Term B Loan due 2021—EUR LIBOR at average floating rates of 3.75%		935			1,030
	Revolving Credit Facility due 2019—USD LIBOR at average floating rates of 2.40%		272			—
	12.5% Senior Notes due 2018		—			1,000
	7.375%/8.125% Senior PIK Toggle Notes due 2018		—			750
	6.00% Senior Notes due 2020		500			500
	Principal Amount of Debt		3,923			5,027
	Less: Unamortized Discounts		(24	)		(67	)
	Total Debt	$	3,899		$	4,960
	Scheduled principal payments due on the Company’s debt as of September 30, 2014 for the remainder of 2014 and thereafter were as follows:
		Year
	(in millions)	2014			2015			2016		2017		2018		Thereafter		Total
	Debt	$	13		$	51		$	51	$	57	$	69	$	3,682	$	3,923
	Senior Secured Credit Facilities
	In March 2014, IMS Health Incorporated (“IMS Health”), an indirect wholly-owned subsidiary of the Company, and certain of its subsidiaries, as co-borrowers, entered into an amendment (the “2014 Amendment”) to amend and restate the Second Amended and Restated Credit and Guaranty Agreement, which until such date governed IMS Health’s Senior Secured Credit Facilities (the amended and restated credit agreement resulting from the 2014 Amendment, the “2014 Credit Agreement”). The 2014 Amendment added commitments in respect of new Term A loans (the “New Term Loans”) in the aggregate dollar equivalent amount of $500 million, increased outstanding commitments under the revolving credit facility to $500 million, modified certain interest rates and covenants and made additional modifications to IMS Health’s Senior Secured Credit Facilities. The commitments in respect of the New Term Loans mature in March 2019. The New Term Loans were funded in April 2014 concurrent with the Company’s IPO. See Note 1 for further information on the IPO. In addition to the New Term Loans, the Company has Term B loan commitments and in March 2014, IMS Health reduced the borrowing margins and the EUR LIBOR floor by 25 basis points each, respectively, extended the maturity date to March 2021 for these existing Term B loans and increased the capacity to $500 million and extended the maturity date to March 2019 for the existing Revolving Credit Facility. As a result of the 2014 Amendment, the Company recorded $11 million of debt extinguishment losses and $2 million of third party fees in Other income (loss), net during the nine months ended September 30, 2014.
	In February 2013, IMS Health and certain of its subsidiaries entered into an amendment of the then existing senior secured term loans due 2017 (“Term Loan Amendment”) to reduce its borrowing costs. IMS Health reduced the borrowing margins and LIBOR floors by 50 basis points and 25 basis points, respectively, for both the USD and EUR tranches of debt. As a result of the Term Loan Amendment, the Company recorded $9 million of debt extinguishment losses and $3 million of third party fees in Other income (loss), net during the nine months ended September 30, 2013.
	In October 2012, IMS Health and certain of its subsidiaries completed a recapitalization (the “Recapitalization”). The Recapitalization included an amendment (the “Amendment”) to its Amended and Restated Credit and Guaranty Agreement for additional term loans and (a) extended the maturity date of the Revolving Credit Facility to August 2017; and (b) increased the maximum leverage ratio.
	IMS Health is required to make scheduled quarterly payments on the Term A loans at rates that vary from 1.25% to 2.50% of the original principal amount of the term loans, with the remaining balance paid at maturity. Additionally IMS Health is required to make scheduled quarterly payments on the Term B loans each equal to approximately 0.25% of the original principal amount of the term loans, with the remaining balance paid at maturity. IMS Health is also required to pay an annual commitment fee that ranges from 0.30% to 0.40% in respect of any unused commitments under the revolving credit facility.
	At September 30, 2014, IMS Health, IMS AG and IMS Japan K.K., as co-borrowers, had a $500 million revolving credit facility, of which $228 million was unused. The Senior Secured Credit Facilities are secured by a security interest in substantially all of Healthcare Technology Intermediate Holdings, Inc.’s, IMS Health’s and the U.S. subsidiary guarantors’ tangible and intangible assets, including the stock of IMS Health and certain of IMS Health’s U.S. restricted subsidiaries and a portion of the stock of IMS Health’s non-U.S. restricted subsidiaries directly owned by Healthcare Technology Intermediate Holdings, Inc., IMS Health or a U.S. subsidiary guarantor. In addition, the obligations of IMS AG are guaranteed by certain of its Swiss restricted subsidiaries and are secured by certain assets of IMS AG and the Swiss guarantors, including the stock of the Swiss guarantors, and the obligations of IMS Japan K.K. are secured by certain of its assets.  There have been no borrowings by IMS AG or IMS Japan K.K. to date.
	Senior Notes
	In February 2010, IMS Health issued an aggregate principal amount of $1 billion of senior unsecured notes due 2018 (“Old 12.5% Senior Notes”). In order to effect the Recapitalization, the Company conducted an exchange offer and consent solicitation to exchange the Old 12.5% Senior Notes for new 12.5% Senior Notes due 2018 (“New 12.5% Senior Notes” and, together with Old 12.5% Senior Notes, “12.5% Senior Notes”), and to solicit consents to proposed amendments to the indenture governing the Old 12.5% Senior Notes to permit the Recapitalization. The requisite consents were obtained and 99.96% of the holders of the Old 12.5% Senior Notes agreed to participate in the exchange and received New 12.5% Senior Notes in an equal principal amount. In connection with the IPO, the 12.5% Senior Notes were redeemed in April 2014 at a price equal to 100% of the principal amount of $1 billion, plus accrued interest of $17 million and a make-whole premium of $136 million. The Company incurred a loss on extinguishment of debt of $189 million in the second quarter of 2014, consisting of the make-whole premium and the write-off of $53 million of debt issuance costs and discounts. See Note 1 for further information on the IPO.
	The Recapitalization also included a new offering of $500 million aggregate principal amount of 6% Senior Notes due 2020 (the “6% Senior Notes”). Interest is payable semi-annually each year. The 6% Senior Notes are guaranteed on a senior unsecured basis by IMS Health’s wholly-owned domestic subsidiaries that are guarantors under the Senior Secured Credit Facilities. The 6% Senior Notes have a three-year no call redemption period.
	Senior PIK Notes
	In August 2013, Healthcare Technology Intermediate, Inc., a wholly-owned subsidiary of the Company, issued $750 million of Senior PIK Notes. The Senior PIK Notes were unsecured obligations of Healthcare Technology Intermediate, Inc. and had a maturity date of September 1, 2018. Interest was to be paid semi-annually in March and September of each year, commencing March 1, 2014. The proceeds, along with cash provided by the Company, were used to pay an approximate $753 million dividend to shareholders of the Company and for the payment of fees and expenses of the transaction of approximately $17 million. In connection with the IPO, the Senior PIK Notes were redeemed in April 2014 at a price equal to 100% of the principal amount of $750 million, plus accrued interest of $6 million and a make-whole premium of $15 million. The Company incurred a loss on extinguishment of debt of $30 million in the second quarter of 2014, consisting of the make-whole premium and the write-off of $15 million of debt issuance costs. See Note 1 for further information on the IPO.
	Costs incurred to issue debt are generally deferred and amortized as a component of interest expense over the estimated term of the related debt using the effective interest rate method. As of September 30, 2014, the unamortized balance of original issue discount reflected as a reduction to long term debt and fees and expenses related to the issuance of the debt included in Other assets was $24 million and $59 million, respectively. The Company recorded interest expense of $3 million and $9 million for the three months ended September 30, 2014 and 2013, respectively, and $15 million and $27 million for the nine months ended September 30, 2014 and 2013, respectively, related to the amortization of these balances.
	The financing arrangements provide for certain covenants and events of default customary for similar instruments, including in the case of the Senior Secured Credit Facilities beginning with the fiscal quarter ending June 30, 2014, a covenant not to exceed a specified ratio of consolidated senior secured net indebtedness to Consolidated EBITDA, as defined in the 2014 Credit Agreement and a covenant to maintain a specified minimum interest coverage ratio. If an event of default occurs under any of the Company’s or the Company’s subsidiaries’ financing arrangements, the creditors under such financing arrangements will be entitled to take various actions, including the acceleration of amounts due under such arrangements, and in the case of the lenders under the revolving credit facility and New Term Loans, other actions permitted to be taken by a secured creditor. At September 30, 2014, the Company was in compliance with the financial covenants under the Company’s financing arrangements.

Pension_and_Postretirement_Ben

Pension and Postretirement Benefits	9 Months Ended
	Sep. 30, 2014
Compensation And Retirement Disclosure [Abstract]	'
Pension and Postretirement Benefits	'
	Note 7. Pension and Postretirement Benefits
	The following table summarizes the components of net periodic benefit cost for the Company’s pension benefits.
		Pension Benefits
		U.S. plans						Non-U.S. plans						U.S. plans						Non-U.S. plans
		Three Months Ended September 30,												Nine Months Ended September 30,
	(in millions)	2014			2013			2014			2013			2014			2013			2014			2013
	Service cost	$	2		$	2		$	1		$	2		$	7		$	8		$	4		$	4
	Interest cost		3			3			3			2			9			7			8			7
	Expected return on plan assets		(5	)		(5	)		(3	)		(3	)		(15	)		(14	)		(9	)		(8	)
	Amortization of net loss		—			1			—			—			—			1			—			—
	Net periodic benefit cost	$	—		$	1		$	1		$	1		$	1		$	2		$	3		$	3
	The Company’s net periodic benefit (credit) cost for its postretirement benefits was a credit of less than $1 million and $1 million for the three and nine months ended September 30, 2014, respectively, and a cost of less than $1 million and $1 million for the three and nine months ended September 30, 2013, respectively. During the nine months ended September 30, 2014, the Company contributed approximately $18 million to its pension and postretirement benefit plans and expects to contribute an additional $2 million for the remainder of 2014.

Shareholders_Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Shareholders' Equity	'
	Note 8. Shareholders’ Equity
	On March 24, 2014, the Company effected a 10-to-1 reverse stock split of its common stock. In connection with the split, the par value of the Company’s common stock changed from $0.001 per share to $0.01 per share. Unless otherwise noted, all references in these financial statements to number of shares, price per share and weighted average number of shares outstanding of common stock have been adjusted to reflect the reverse stock split on a retroactive basis. The split also applied to any outstanding equity-based awards.
	The Company amended its Certificate of Incorporation on April 9, 2014, in connection with the closing of the IPO. The Amended and Restated Certificate of Incorporation authorizes the Board of Directors, at its discretion, to issue up to 50,000,000 shares of preferred stock with a par value of $0.01 per share. The preferred stock is issuable in series, which may vary as to certain rights and preferences. As of September 30, 2014, no preferred shares have been issued. The Amended and Restated Certificate of Incorporation also set the number of authorized common shares at 700,000,000 shares.

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock-Based Compensation	'
	Note 9. Stock-Based Compensation
	In March 2014, the Company’s board of directors adopted the IMS Health Holdings, Inc. 2014 Incentive and Stock Award Plan (the “2014 Equity Plan”). Both annual award opportunities and equity-based awards for certain key employees, including the Company’s named executive officers, non-employee directors, consultants and other persons who provide substantial services to the Company, are granted under the 2014 Equity Plan. The 2014 Equity Plan provides for grants of stock options (including incentive stock options), stock appreciation rights, restricted and deferred stock (including restricted stock units), dividend equivalents, other stock-based awards and performance awards, including annual incentive awards.
	In the first nine months of 2014, the Company granted to employees options to purchase 135,000 shares of its common stock in the aggregate, at an exercise price equal to $19.50, 15,000 cash settled stock appreciation rights (“Phantom SARs”) at an exercise price equal to $19.50, and granted to employees and non-employee directors approximately 1,442,000 restricted stock units. The stock options are subject to time- and performance-based vesting over a five-year period. The Phantom SARs vested and were automatically exercised at the time of the IPO. See Note 1 for further information. The restricted stock units granted to employees vest in equal increments of fifty percent on each of the second and fourth anniversaries of the grant date. The restricted stock units granted to non-employee directors vest in full on the first anniversary of the grant date. The stock options and Phantom SARs were granted under the 2010 Equity Plan and the restricted stock units were granted under both the 2010 Equity Plan and the 2014 Equity Plan.
	In August 2013, the board of directors of the Company declared a cash dividend of $2.60 per share. In accordance with the terms of the 2010 Equity Plan, option holders received $2.60 per share in respect of vested options and a corresponding $2.60 per share reduction in the exercise price of unvested options. The other terms of the equity awards, including vesting schedules, remained unchanged. The Company did not record a charge for modification of the exercise price for unvested awards as the modification was provided for by the terms of the 2010 Equity Plan.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Note 10. Income Taxes
	The Company operates in more than 100 countries around the world and its earnings are taxed at the applicable income tax rate in each of these countries. As required, the Company computes interim taxes based on an estimated annual effective tax rate.
	The Company recorded a provision for income taxes of $11 million for the three months ended September 30, 2014 and a benefit for income taxes of $141 million for the nine months ended September 30, 2014, which resulted in effective tax rates of 20.4% and 41.6%, respectively. The tax provision for the three months ended September 30, 2014 was primarily impacted by non-taxable income in the U.S. related to a change in the fair value of a contingent consideration liability. The tax benefit for the nine months ended September 30, 2014 was primarily due to a significant amount of deductible expenses in the U.S. related to the redemption of the Company’s 12.5% Senior Notes and Senior PIK Notes, the termination of the management services agreement with affiliates of the Sponsors, and non-executive Phantom SARs compensation expense. In addition, the effective tax rate in both periods was impacted as a result of profits generated in non-U.S. tax jurisdictions with lower tax rates than the U.S. statutory tax rate and by deferred U.S. income tax expense related to non-U.S. earnings net of associated tax credits. The Company also recorded a tax benefit of $6 million in the second quarter of 2014 as a result of the conclusion of a U.S. Federal income tax examination for 2010 and 2011. Also, under Financial Accounting Standards Board Interpretation No. 48, “Accounting for Uncertainty in Income Taxes” (“FIN 48”) (now incorporated into Accounting Standards Codification Topic 740, Income Taxes), the Company recorded $5 million of tax expense related to unrecognized tax benefits that if recognized would favorably impact the effective tax rate. Included in this amount is $2 million of interest and penalties.
	The Company recorded a benefit for income taxes of $20 million for the three months ended September 30, 2013 and $6 million for the nine months ended September 30, 2013, which resulted in effective tax rates of 50.5% and 97.0%, respectively. The tax benefit in both periods was impacted as a result of profits generated in non-U.S. tax jurisdictions with lower tax rates than the U.S. statutory tax rate and by deferred U.S. income tax expense related to non-U.S. earnings net of associated tax credits.  In addition, the tax benefit in both periods was impacted by a tax reduction of $10 million as a result of the conclusion of U.S. audits. Also, under FIN 48, the Company recorded $4 million of tax expense related to unrecognized tax benefits that if recognized would favorably impact the effective tax rate. Included in this amount is $2 million of interest and penalties.
	The Company files numerous consolidated and separate income tax returns in U.S. (federal and state) and non-U.S. jurisdictions. The Company is no longer subject to U.S. federal income tax examination by tax authorities for years before 2012. Further, with few exceptions, the Company is no longer subject to tax examination in state and local jurisdictions for years prior to 2009 and in its material non-U.S. jurisdictions prior to 2008. It is reasonably possible that within the next twelve months the Company could realize $2 million of unrecognized tax benefits as a result of the expiration of certain statutes of limitation.

Contingencies

Contingencies	9 Months Ended
	Sep. 30, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Contingencies	'
	Note 11. Contingencies
	The Company and its subsidiaries are involved in legal and tax proceedings, claims and litigation arising in the ordinary course of business. Management periodically assesses the Company’s liabilities and contingencies in connection with these matters based upon the latest information available. For those matters where management currently believes it is probable that the Company will incur a loss and that the probable loss or range of loss can be reasonably estimated, the Company has recorded reserves in the Condensed Consolidated Financial Statements based on its best estimates of such loss. In other instances, because of the uncertainties related to either the probable outcome or the amount or range of loss, management is unable to make a reasonable estimate of a liability, if any. However, even in many instances where the Company has recorded an estimated liability, the Company is unable to predict with certainty the final outcome of the matter or whether resolution of the matter will materially affect the Company’s results of operations, financial position or cash flows. As additional information becomes available, the Company adjusts its assessments and estimates of such liabilities accordingly.
	The Company routinely enters into agreements with its suppliers to acquire data and with its clients to sell data, all in the normal course of business. In these agreements, the Company sometimes agrees to indemnify and hold harmless the other party for any damages such other party may suffer as a result of potential intellectual property infringement and other claims related to the use of the data. The Company has not accrued a liability with respect to these matters, as the exposure is considered remote.
	Based on its review of the latest information available, management does not expect the impact of pending tax and legal proceedings, claims and litigation, either individually or in the aggregate, to have a material adverse effect on the Company’s results of operations, cash flows or financial position. However, one or more unfavorable outcomes in any claim or litigation against the Company could have a material adverse effect for the period in which it is resolved. The following is a summary of certain legal matters involving the Company.
	IMS Health Government Solutions Voluntary Disclosure Program Participation
	The Company’s wholly-owned subsidiary, IMS Government Solutions Inc. (“IMS Government Solutions”), is primarily engaged in providing services and products under contracts with the U.S. government. U.S. government contracts are subject to extensive legal and regulatory requirements and, from time to time, agencies of the U.S. government have the ability to investigate whether contractors’ operations are being conducted in accordance with such requirements. U.S. government investigations, whether relating to these contracts or conducted for other reasons, could result in administrative, civil or criminal liabilities, including repayments, fines or penalties being imposed on us, or could lead to suspension or debarment from future U.S. government contracting. U.S. government investigations often take years to complete and may result in no adverse action against the Company.
	IMS Government Solutions discovered potential noncompliance with various contract clauses and requirements under its General Services Administration Contract (the “GSA Contract”) which was awarded in 2002 to its predecessor company, Synchronous Knowledge Inc. (Synchronous Knowledge Inc. was acquired by IMS Health in May 2005). The potential noncompliance arose from three primary areas: first, at the direction of the government, work performed under one task order was invoiced under another task order without the appropriate modifications to the orders being made; second, personnel who did not meet strict compliance with the labor categories component of the qualification requirements of the GSA Contract were assigned to contracts; and third, certain discounts that were given to commercial customers were not also offered to the government, in alleged violation of the GSA Contract’s Price Reductions Clause. Upon discovery of the potential noncompliance, the Company began remediation efforts, promptly disclosed the potential noncompliance to the U.S. government, and was accepted into the Department of Defense Voluntary Disclosure Program. The Company filed its Voluntary Disclosure Program Report (“Disclosure Report”) on August 29, 2008. Based on the Company’s findings as disclosed in the Disclosure Report, the Company recorded a reserve of approximately $4 million for this matter in 2008. During 2010, the Company recorded an additional reserve of approximately $2 million as a result of its ongoing investigation relating to this matter. In September 2014, the General Services Administration offered to settle the third matter described above (i.e., the Price Reductions Clause aspect of the Disclosure Report) for $1.5 million, in-line with the amount the Company had recorded for this area of potential noncompliance. The Company is discussing the terms of settlement with the government for this Price Reductions Clause issue. The Company is currently unable to determine the outcome of all of these matters pending the resolution of the Voluntary Disclosure Program process and its ultimate liability arising from these matters could exceed its current reserves.
	Symphony Health Solutions litigation
	On July 24, 2013, Symphony Health Solutions filed a lawsuit in the U.S. District Court for the Eastern District of Pennsylvania against IMS Health alleging that IMS Health is actively engaging in anticompetitive business practices in violation of the Sherman Antitrust Act and Pennsylvania state law. The complaint seeks trebled actual damages in an unspecified amount, punitive damages, costs and injunctive relief. The Company believes the complaint is without merit, rejects all claims raised and will vigorously defend IMS Health’s position.

Related_Party

Related Party	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Related Party	'
	Note 12. Related Party
	Due to related party relationships, it is possible that the terms of these transactions are not the same as those that would result from transactions among wholly unrelated parties.
	Management services agreement
	The Company had a management services agreement with affiliates of the Sponsors pursuant to which they would provide management services to the Company. In conjunction with the Company’s IPO, the management services agreement was terminated for a settlement amount of $72 million and the Company recorded this charge as a component of Selling and administrative expenses, exclusive of depreciation and amortization in the Condensed Consolidated Statements of Comprehensive (Loss) Income in the second quarter of 2014. Prior to the termination of the management services agreement, the Company paid an additional $2 million during the first quarter of 2014 in management fees pursuant to the management services agreement. During the three and nine months ended September 30, 2013, the Company paid $2 million and $6 million, respectively, in management fees.
	Transactions with other Sponsor portfolio companies
	The Sponsors are private equity firms that have investments in companies that do business with IMS Health in the ordinary course of business. The Company believes these transactions are conducted on an arms-length basis. The following is a summary of the activity with companies in which the Sponsors have investments:
			Three Months Ended						Nine Months Ended
			September 30,						September 30,
	(in millions)		2014			2013			2014			2013
	Revenues(1)		$	1		$	2		$	5		$	7
	Expenses(2)			(1	)		(2	)		(5	)		(4	)
	-1	Sales of the Company’s offerings to companies in which the Sponsors have investments.
	-2	Purchases of goods and services from companies in which the Sponsors have investments.

Operations_by_Business_Segment

Operations by Business Segment	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Operations by Business Segment	'
	Note 13. Operations by Business Segment
	Operating segments are defined as components of an enterprise about which financial information is available that is evaluated on a regular basis by the chief operating decision-maker, or decision-making groups, in deciding how to allocate resources to an individual segment and in assessing performance of the segment. The Company operates a globally consistent business model, offering pharmaceutical business information and related services to its clients in more than 100 countries.
	The Company maintains regional geographic management who are responsible for bringing the Company’s full suite of offerings to their respective markets and to facilitate local execution of its global strategies. However, the Company maintains global leaders for the majority of its critical business processes; and the most significant performance evaluations and resource allocations made by the Company’s chief operating decision maker is made on a global basis. As such, the Company has concluded that it maintains one operating and reportable segment.
	Geographic financial information:
	The following represents selected geographic information for the regions in which the Company operates.
	(in millions)		Americas(1)		EMEA(2)		Asia		Corporate			Total
							Pacific(3)		& Other
	Three Months Ended September 30
	2014
	Revenue(4)		$	303	$	240	$	113	$	-		$	656
	Operating income (loss)(5)			71		57		35		(70	)		93
	2013
	Revenue(4)		$	294	$	227	$	112	$	-		$	633
	Operating income (loss)(5)			78		58		39		(75	)		100
	Nine Months Ended September 30
	2014
	Revenue(4)		$	887	$	739	$	337	$	-		$	1,963
	Operating income (loss)(5)			204		183		103		(369	)		121
	2013
	Revenue(4)		$	851	$	682	$	337	$	-		$	1,870
	Operating income (loss)(5)			224		176		117		(241	)		276
	Notes to Geographic Financial Information:
	-1	Americas includes the United States, Canada and Latin America. Revenue in the United States was $249 million and $233 million for the third quarters of 2014 and 2013, respectively, and $718 million and $682 million for the first nine months of 2014 and 2013, respectively.
	-2	EMEA includes countries in Europe, the Middle East and Africa.
	-3	Asia Pacific includes Japan, Australia and other countries in the Asia Pacific region. Revenue in Japan was $63 million and $66 million for the third quarters of 2014 and 2013, respectively and $193 million and $200 million for the first nine months of 2014 and 2013, respectively.
	-4	Revenue relates to external clients and is primarily based on the location of the client. Revenue for the geographic regions includes the impact of foreign exchange in converting results into U.S. dollars.
	-5	Operating income (loss) for the three geographic regions does not reflect the allocation of certain expenses that are maintained in Corporate and Other and as such, is not a true measure of the respective regions’ profitability. The Operating income (loss) amounts for the geographic segments include the impact of foreign exchange in converting results into U.S. dollars. The following presents the depreciation and amortization related to purchase accounting adjustments for each region that are presented in Corporate and Other:
	(in millions)		Americas		EMEA		Asia Pacific
	Three Months Ended September 30
	2014		$	31	$	21	$	10
	2013			31		22		10
	Nine Months Ended September 30
	2014		$	94	$	66	$	30
	2013			94		65		32

Earnings_per_Share

Earnings per Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Earnings per Share	'
	Note 14. Earnings per Share
	Basic earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed, when the result is dilutive, using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of employee stock options and restricted stock units.
	Employee stock options, restricted stock units and similar equity instruments granted by the Company are treated as potential common shares outstanding in computing diluted earnings per share. Diluted shares outstanding include restricted stock units and the dilutive effect of in-the-money options which is calculated based on the average share price for each fiscal period using the treasury stock method. Under the treasury stock method, the amount the employee must pay for exercising stock options, the amount of compensation cost for future service that the Company has not yet recognized, and the amount of benefits that would be recorded in additional paid-in capital when the award becomes deductible for tax purposes are assumed to be used to repurchase shares.
	In periods of net loss, basic loss per share and diluted loss per share are the same since the effect of potential common shares is anti-dilutive and therefore excluded.
	The following table presents the composition of basic and diluted weighted average shares outstanding:
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
	(Shares in millions)	2014		2013		2014		2013
	Basic weighted-average common shares outstanding		332.1		280		314.1		280
	Effect of dilutive stock-based awards		10.2		—		—		—
	Diluted weighted-average common shares outstanding		342.3		280		314.1		280
	Shares excluded from computation of diluted earnings (loss) per share:
	Weighted average potential common shares excluded from computation due to anti-dilutive effect		—		18.9		19.1		18.9

Basis_of_Presentation_and_Rece1

Basis of Presentation and Recently Issued Accounting Standards (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. The Condensed Consolidated Financial Statements do not include all the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, all of which are of a normal recurring nature, considered necessary for a fair statement of financial position, results of operations and comprehensive loss, cash flows and shareholders’ equity for the periods presented have been included. The results of operations for interim periods are not necessarily indicative of the results expected for the full year. The December 31, 2013 Condensed Consolidated Statement of Financial Position was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The Condensed Consolidated Financial Statements and related notes should be read in conjunction with the audited Consolidated Financial Statements and related notes of IMS Health Holdings, Inc. included in the Company’s prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, with the Securities and Exchange Commission (the “SEC”) on April 4, 2014 (the “Prospectus”). Certain prior year amounts have been reclassified to conform to the 2014 presentation. Amounts presented in the Condensed Consolidated Financial Statements may not add due to rounding.
Recently Issued Accounting Standards	'
	Recently Issued Accounting Standards
	In August 2014, the Financial Accounting Standards Board (“FASB”) issued guidance on management’s responsibility to assess an entity’s ability to continue as a going concern and provide related footnote disclosures in certain circumstances.  The guidance is effective for the Company’s interim and annual periods beginning after December 15, 2016.  The Company does not believe the adoption of this guidance will impact its consolidated financial statements or disclosures.
	In June 2014, the FASB issued guidance on accounting for share-based payments that a performance target that affects vesting and could be achieved after the requisite service period be treated as a performance condition. The guidance is effective for the Company’s interim and annual periods beginning January 1, 2016. The Company does not believe the adoption of this guidance will have a material impact to its consolidated financial statements.
	In May 2014, the FASB issued revised guidance on the recognition of revenue from contracts with customers. The guidance provides that revenue should be recognized for the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires enhanced disclosures and is effective for the Company’s interim and annual periods beginning January 1, 2017. The Company is currently evaluating this guidance to determine any potential impact that it may have on its financial results.
Debt Issuance	'
	Costs incurred to issue debt are generally deferred and amortized as a component of interest expense over the estimated term of the related debt using the effective interest rate method.
Income Taxes	'
	As required, the Company computes interim taxes based on an estimated annual effective tax rate.
Contingencies	'
	For those matters where management currently believes it is probable that the Company will incur a loss and that the probable loss or range of loss can be reasonably estimated, the Company has recorded reserves in the Condensed Consolidated Financial Statements based on its best estimates of such loss. In other instances, because of the uncertainties related to either the probable outcome or the amount or range of loss, management is unable to make a reasonable estimate of a liability, if any. However, even in many instances where the Company has recorded an estimated liability, the Company is unable to predict with certainty the final outcome of the matter or whether resolution of the matter will materially affect the Company’s results of operations, financial position or cash flows. As additional information becomes available, the Company adjusts its assessments and estimates of such liabilities accordingly.
Earnings per Share	'
	Basic earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed, when the result is dilutive, using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of employee stock options and restricted stock units.
Derivatives	'
	The forward contracts entered into for balance sheet risk management purposes are not designated as hedges and are carried at fair value, with changes in the fair value recorded to Other income (loss), net in the Condensed Consolidated Statements of Comprehensive (Loss) Income. These contracts do not subject the Company to material balance sheet risk because gains and losses on these derivatives are intended to offset gains and losses on the assets and liabilities being hedged.
	Unrealized and realized gains and losses on the contracts entered into for managing foreign exchange movement on EBITDA did not qualify for hedge accounting, and therefore were not deferred and were included in the Condensed Consolidated Statements of Comprehensive (Loss) Income in Other income (loss), net.
	The forward contracts entered into for Royalty Hedging purposes are designated as hedges and are carried at fair value, with changes in the fair value recorded to Accumulated Other Comprehensive Income (Loss) (“AOCI”). The change in fair value is reclassified from AOCI to earnings in the quarter in which the hedged royalty is paid.
	For derivatives designated as hedges, the Company assesses, both at the inception of the hedge and on an ongoing basis, whether the derivatives are highly effective in offsetting changes in fair values or cash flows of hedged items. If it is determined that a derivative ceases to be highly effective as a hedge, the Company will discontinue hedge accounting with respect to that derivative prospectively. When it is probable that a hedged forecasted transaction will not occur, the Company discontinues hedge accounting for the affected portion of the forecasted transaction, and reclassifies gains or losses that were accumulated in AOCI to earnings in Other income (loss), net on the Condensed Consolidated Statements of Comprehensive (Loss) Income. Cash flows are classified consistent with the underlying hedged item.
	In April 2014, the Company designated Euro currency borrowings as hedges of its foreign currency exposures of the net investment in certain foreign affiliates. As of September 30, 2014, these borrowings (net of original issue discount) were €869 million ($1,093 million). The effective portion of foreign exchange gains or losses on the remeasurement of the debt is recognized in the cumulative translation adjustment component of AOCI with the related offset in long-term debt. Those amounts would be reclassified from AOCI to earnings upon the sale or substantial liquidation of these net investments. The amount of foreign exchange gains related to the net investment hedges included in cumulative translation adjustment for the three and nine months ended September 30, 2014 was $94 million and $105 million, respectively.
	Changes in the fair value of derivatives that are designated as cash flow hedges are recorded in AOCI to the extent effective and reclassified into earnings in the same period or periods during which the transaction hedged by that derivative also affects earnings. The Company expects $17 million of pre-tax unrealized losses related to its foreign exchange contracts and interest rate derivatives included in AOCI at September 30, 2014 to be reclassified into earnings within the next twelve months.

Goodwill_and_Identifiable_Inta1

Goodwill and Identifiable Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Summary of Changes in Goodwill	'
	The following table sets forth changes in the Company’s goodwill for the nine months ended September 30, 2014.
	(in millions)	Goodwill
	Balance at December 31, 2013	$	3,573
	Goodwill assigned in purchase price allocations (see Note 2)		31
	Foreign currency translation adjustments and other		(104	)
	Balance at September 30, 2014	$	3,500
Schedule of Intangible Assets	'
	The gross carrying amounts, related accumulated amortization and the weighted average amortization periods of the Company’s intangible assets are listed in the following table:
		30-Sep-14								December 31, 2013
	(in millions)	Gross			Accumulated			Weighted Average		Gross		Accumulated
		Carrying			Amortization			Amortization		Carrying		Amortization
		Amount						Period (Years)		Amount
	Databases	$	696		$	(628	)		0.5	$	725	$	(549	)
	Client Relationships and other		2,132			(580	)		14		2,152		(491	)
	Trade Names (Finite-Lived)		145			(37	)		14.1		151		(31	)
	Trade Names (Indefinite-Lived)		537			—			N/A		560		—
	Total Intangible Assets	$	3,510		$	(1,245	)		10.8	$	3,588	$	(1,071	)
Schedule of Amortization Expense Associated With Intangible Assets	'
	Based on current estimated useful lives, amortization expense associated with intangible assets at September 30, 2014 is estimated to be as follows:
	(in millions)	Amortization
	Year ended December 31,	Expense
	Remainder of 2014	$	71
	2015		176
	2016		149
	2017		136
	2018		133
	Thereafter		1,063

Severance_Impairment_and_Other1

Severance, Impairment and Other Charges (Tables)	9 Months Ended
	Sep. 30, 2014
Restructuring And Related Activities [Abstract]	'
Schedule of Severance Related Reserves	'
	As a result of ongoing cost reduction efforts, the Company recorded severance charges consisting of global workforce reductions to streamline its organization. The following table sets forth the activity in the Company’s severance-related reserves for the nine months ended September 30, 2014:
	(in millions)		2014 Plan(1)			2013 Plan(2)			2012 Plan(3)
	Balance at December 31, 2013		$	—		$	12		$	6
	Charges			19			—			—
	Cash payments			(7	)		(4	)		(3	)
	Balance at September 30, 2014		$	12		$	8		$	3
	(1)	In May 2014, the Company implemented a restructuring plan (the “2014 Plan”) and recorded a pre-tax severance charge of $15 million. In September 2014, the Company recorded an additional pre-tax severance charge of $4 million under the 2014 Plan.  The Company expects that cash outlays related to the 2014 Plan will be substantially complete by the end of 2015.
	(2)	In December 2013, the Company implemented a restructuring plan (the “2013 Plan”) and recorded a pre-tax severance charge of $12 million. The Company expects that cash outlays related to the 2013 Plan will be substantially complete by the end of 2015.
	(3)	In December 2012, the Company implemented a restructuring plan (the “2012 Plan”) and recorded a pre-tax severance charge of $23 million. In the third quarter of 2013, $6 million of severance accruals were reversed due to the favorable settlement of required termination benefits and strategic business changes. The Company expects that cash outlays related to the 2012 Plan will be substantially complete by the end of 2014.

Derivatives_and_Fair_Value_Tab

Derivatives and Fair Value (Tables)	9 Months Ended
	Sep. 30, 2014
Derivatives And Fair Value Disclosure [Abstract]	'
Schedule of Components of Foreign Exchange Gain (loss)	'
	The following table details the components of foreign exchange gain (loss) included in Other income (loss), net on the Condensed Consolidated Statements of Comprehensive (Loss) Income:
			Three Months Ended						Nine Months Ended
			September 30,						September 30,
	(in millions)		2014			2013			2014				2013
	Translation of non-functional currency debt		$	—		$	(34	)	$	—			$	(22	)
	Revaluation of other non-functional currency assets and liabilities(1)			8			(17	)		(48	)			(14	)
	Effect of derivatives			(4	)		—			(4	)			7
	Total foreign exchange gain (loss)		$	4		$	(51	)	$	(52	)		$	(29	)
	-1	The nine months ended September 30, 2014 included a $49 million charge related to a change in the exchange rate used to remeasure the Company’s Venezuelan Bolívar account balances. Additionally, the nine months ended September 30, 2013 included a $14 million charge resulting from devaluation of Venezuelan Bolívars. Both the 2014 and 2013 charges are further described below in this Note.
Schedule of Fair Value of Derivative Instruments	'
	The fair values of derivative instruments in the Condensed Consolidated Statements of Financial Position are as follows:
						30-Sep-14											31-Dec-13
						Fair Value of Derivative							U.S. Dollar				Fair Value of Derivative				U.S. Dollar
	(in millions)				Balance Sheet Caption	Asset			Liability				Notional				Asset		Liability		Notional
	Derivatives designated as hedging instruments
	Foreign exchange contracts				Accounts receivable/Accounts payable	$	13		$	—			$	215			$	6	$	4	$	202
	Interest rate caps				Non-Current Assets		16			—				1,000				—		—		—
	Interest rate swaps				See below(1)		—			10				565				—		—		—
	Derivatives not designated as hedging instruments
	Foreign exchange contracts				Accounts receivable/Accounts payable		4			7				228				3		11		219
	Interest rate caps				—		—			—				110				—		—		365
	Interest rate swaps				See below(1)		—			6				225				—		12		375
	Total derivatives					$	33		$	23							$	9	$	27
	-1	$2 million included in Accrued and other current liabilities and $14 million included in Other liabilities at September 30, 2014 and $12 million included in Other liabilities at December 31, 2013 in the Condensed Consolidated Statements of Financial Position.
Schedule of Effect of Derivatives on Financial Performance	'
	The effects of derivative instruments on the Condensed Consolidated Statements of Comprehensive (Loss) Income are as follows:
	(in millions)		Effect of Derivatives on Financial Performance
	Derivatives in Cash Flow Hedging Relationships		Amount of Income/(Loss)						Location of Income/(Loss)		Amount of
			Recognized in AOCI						Reclassified from AOCI into		Income/(Loss)
									Earnings		Reclassified from
											AOCI
											into Earnings
	Three Months Ended September 30,		2014			2013					2014				2013
	Foreign exchange contracts		$	15		$	(5	)	Other income (loss), net		$	1			$	4
	Interest rate derivatives			(3	)		—		Interest expense			(2	)			—
	Nine Months Ended September 30,			2014			2013					2014				2013
	Foreign exchange contracts		$	12		$	9		Other income (loss), net		$	1			$	11
	Interest rate derivatives			(16	)		—		Interest expense			(2	)			—
Schedule of Pre-tax Gain (Loss) Recognized in Earnings on Derivatives Not Designated as Hedging Instruments	'
	The pre-tax gain (loss) recognized in earnings on derivatives not designated as hedging instruments was as follows:
			Three Months Ended						Nine Months Ended
			September 30,						September 30,
	(in millions)		2014			2013			2014				2013
	Foreign exchange contracts(1)		$	(5	)	$	(4	)	$	(5	)		$	(4	)
	Interest rate derivatives(2)			—			2			—				7
	Total derivatives not designated as hedging instruments		$	(5	)	$	(2	)	$	(5	)		$	3
	-1	Included in Other income (loss), net
	-2	Included in interest expense
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis	'
	The following tables summarize assets and liabilities measured at fair value on a recurring basis at the dates indicated:
			Basis of Fair Value Measurements
			30-Sep-14
	(in millions)		Level 1			Level 2			Level 3				Total
	Assets
	Short-term investments		$	—		$	1		$	—			$	1
	Derivatives			—			33			—				33
	Total		$	—		$	34		$	—			$	34
	Liabilities
	Contingent consideration		$	—		$	—		$	25			$	25
	Derivatives			—			23			—				23
	Total		$	—		$	23		$	25			$	48
			December 31, 2013
	(in millions)		Level 1			Level 2			Level 3				Total
	Assets
	Short-term investments		$	—		$	4		$	—			$	4
	Derivatives			—			9			—				9
	Total		$	—		$	13		$	—			$	13
	Liabilities
	Contingent consideration		$	—		$	—		$	65			$	65
	Derivatives			—			27			—				27
	Total		$	—		$	27		$	65			$	92
Schedule of Level 3 Acquisition-Related Contingent Consideration Liabilities Carried at Fair Value on a Recurring Basis	'
	The following table summarizes Level 3 acquisition-related contingent consideration liabilities (see Note 2) carried at fair value on a recurring basis with the use of unobservable inputs for the period indicated.
	(in millions)		Contingent
			Consideration
			Liabilities
	Balance at December 31, 2013		$	65
	New acquisitions			3
	Cash payments			(28	)
	Changes in fair value estimates included in Selling and administrative expenses			(15	)
	Balance at September 30, 2014		$	25

Debt_Tables

Debt (Tables)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Schedule of Debt	'
	The following table summarizes the Company’s debt at the dates indicated:
	(in millions)	September 30,			December 31,
		2014			2013
	Senior Secured Credit Facilities:
	Senior Secured Term A Loan due 2019—USD LIBOR at average floating rates of 2.48%	$	311		$	—
	Senior Secured Term A Loan due 2019—EUR LIBOR at average floating rates of 2.31%		166			—
	Senior Secured Term B Loan due 2021—USD LIBOR at average floating rates of 3.50%		1,739			1,747
	Senior Secured Term B Loan due 2021—EUR LIBOR at average floating rates of 3.75%		935			1,030
	Revolving Credit Facility due 2019—USD LIBOR at average floating rates of 2.40%		272			—
	12.5% Senior Notes due 2018		—			1,000
	7.375%/8.125% Senior PIK Toggle Notes due 2018		—			750
	6.00% Senior Notes due 2020		500			500
	Principal Amount of Debt		3,923			5,027
	Less: Unamortized Discounts		(24	)		(67	)
	Total Debt	$	3,899		$	4,960
Schedule of Maturities of Long-Term Debt	'
	Scheduled principal payments due on the Company’s debt as of September 30, 2014 for the remainder of 2014 and thereafter were as follows:
		Year
	(in millions)	2014			2015			2016		2017		2018		Thereafter		Total
	Debt	$	13		$	51		$	51	$	57	$	69	$	3,682	$	3,923

Pension_and_Postretirement_Ben1

Pension and Postretirement Benefits (Tables)	9 Months Ended
	Sep. 30, 2014
Compensation And Retirement Disclosure [Abstract]	'
Components of Net Periodic Benefit Cost	'
	The following table summarizes the components of net periodic benefit cost for the Company’s pension benefits.
		Pension Benefits
		U.S. plans						Non-U.S. plans						U.S. plans						Non-U.S. plans
		Three Months Ended September 30,												Nine Months Ended September 30,
	(in millions)	2014			2013			2014			2013			2014			2013			2014			2013
	Service cost	$	2		$	2		$	1		$	2		$	7		$	8		$	4		$	4
	Interest cost		3			3			3			2			9			7			8			7
	Expected return on plan assets		(5	)		(5	)		(3	)		(3	)		(15	)		(14	)		(9	)		(8	)
	Amortization of net loss		—			1			—			—			—			1			—			—
	Net periodic benefit cost	$	—		$	1		$	1		$	1		$	1		$	2		$	3		$	3

Related_Party_Tables

Related Party (Tables)	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Summary of Activity with Sponsors	'
	The following is a summary of the activity with companies in which the Sponsors have investments:
			Three Months Ended						Nine Months Ended
			September 30,						September 30,
	(in millions)		2014			2013			2014			2013
	Revenues(1)		$	1		$	2		$	5		$	7
	Expenses(2)			(1	)		(2	)		(5	)		(4	)
	-1	Sales of the Company’s offerings to companies in which the Sponsors have investments.
	-2	Purchases of goods and services from companies in which the Sponsors have investments.

Operations_by_Business_Segment1

Operations by Business Segment (Tables)	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Schedule of Geographic Information for Operating Regions	'
	The following represents selected geographic information for the regions in which the Company operates.
	(in millions)		Americas(1)		EMEA(2)		Asia		Corporate			Total
							Pacific(3)		& Other
	Three Months Ended September 30
	2014
	Revenue(4)		$	303	$	240	$	113	$	-		$	656
	Operating income (loss)(5)			71		57		35		(70	)		93
	2013
	Revenue(4)		$	294	$	227	$	112	$	-		$	633
	Operating income (loss)(5)			78		58		39		(75	)		100
	Nine Months Ended September 30
	2014
	Revenue(4)		$	887	$	739	$	337	$	-		$	1,963
	Operating income (loss)(5)			204		183		103		(369	)		121
	2013
	Revenue(4)		$	851	$	682	$	337	$	-		$	1,870
	Operating income (loss)(5)			224		176		117		(241	)		276
	Notes to Geographic Financial Information:
	-1	Americas includes the United States, Canada and Latin America. Revenue in the United States was $249 million and $233 million for the third quarters of 2014 and 2013, respectively, and $718 million and $682 million for the first nine months of 2014 and 2013, respectively.
	-2	EMEA includes countries in Europe, the Middle East and Africa.
	-3	Asia Pacific includes Japan, Australia and other countries in the Asia Pacific region. Revenue in Japan was $63 million and $66 million for the third quarters of 2014 and 2013, respectively and $193 million and $200 million for the first nine months of 2014 and 2013, respectively.
	-4	Revenue relates to external clients and is primarily based on the location of the client. Revenue for the geographic regions includes the impact of foreign exchange in converting results into U.S. dollars.
	-5	Operating income (loss) for the three geographic regions does not reflect the allocation of certain expenses that are maintained in Corporate and Other and as such, is not a true measure of the respective regions’ profitability. The Operating income (loss) amounts for the geographic segments include the impact of foreign exchange in converting results into U.S. dollars. The following presents the depreciation and amortization related to purchase accounting adjustments for each region that are presented in Corporate and Other:
	(in millions)		Americas		EMEA		Asia Pacific
	Three Months Ended September 30
	2014		$	31	$	21	$	10
	2013			31		22		10
	Nine Months Ended September 30
	2014		$	94	$	66	$	30
	2013			94		65		32

Earnings_per_Share_Tables

Earnings per Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Composition of Basic and Diluted Weighted Average Shares Outstanding	'
	The following table presents the composition of basic and diluted weighted average shares outstanding:
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
	(Shares in millions)	2014		2013		2014		2013
	Basic weighted-average common shares outstanding		332.1		280		314.1		280
	Effect of dilutive stock-based awards		10.2		—		—		—
	Diluted weighted-average common shares outstanding		342.3		280		314.1		280
	Shares excluded from computation of diluted earnings (loss) per share:
	Weighted average potential common shares excluded from computation due to anti-dilutive effect		—		18.9		19.1		18.9

Basis_of_Presentation_and_Rece2

Basis of Presentation and Recently Issued Accounting Standards - Additional Information (Detail) (USD $)

9 Months Ended

0 Months Ended

9 Months Ended

12 Months Ended

In Millions, except Per Share data, unless otherwise specified

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Apr. 09, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

12.5% Senior Notes due 2018

12.5% Senior Notes due 2018

IPO

IPO

IPO

IPO

IPO

IPO

Sales

Minimum

2010 Equity Incentive Plan

New Term Loans

Revolving Credit Facility

12.5% Senior Notes due 2018

Country

Basis Of Presentation And Recent Accounting Pronouncements [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Number of countries in which the company transacts business

'

'

'

'

'

'

'

'

'

'

'

100

Percentage of revenue generated from outside the United States

'

'

'

'

'

'

'

'

'

'

63.00%

'

Common stock price per share

'

'

'

'

$20

'

'

'

'

'

'

'

Common stock issued and sold in public offering

'

'

'

'

52

'

'

'

'

'

'

'

Common stock offered and sold in public offering by selling shareholders

'

'

'

'

22.75

'

'

'

'

'

'

'

Exercise of underwriters' allotment, stock issued

'

'

'

'

9.75

'

'

'

'

'

'

'

Proceeds from issuance of common stock after underwriting discounts, commission and related expenses

$987

'

'

'

$987

'

'

'

'

'

'

'

Underwriting discounts, commissions and related expenses

'

'

'

'

53

'

'

'

'

'

'

'

Borrowings under New Term Loans

3,923

5,027

'

1,000

'

'

'

500

'

'

'

'

Borrowings under line of credit

'

'

'

'

'

'

'

'

140

'

'

'

Cash

'

'

'

'

'

400

'

'

'

'

'

'

Debt instrument, interest rate

'

'

12.50%

'

'

'

'

'

'

12.50%

'

'

Cash paid to stock appreciation right holders

'

'

'

'

'

'

30

'

'

'

'

'

One-time fee paid to terminate management services agreement

'

'

'

'

'

$72

'

'

'

'

'

'

Acquisitions_Additional_Inform

Acquisitions - Additional Information (Detail) (USD $)	9 Months Ended		9 Months Ended			3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
			Client Relationships And Other	Databases	Computer software	Acquisitions during the period	Acquisitions during the period
Business Acquisition [Line Items]	'	'	'	'	'	'	'
Total cost of acquisitions	'	'	'	'	'	'	$60
Acquisitions cost paid	'	'	'	'	'	'	56
Acquisition-related costs	'	'	'	'	'	2	3
Goodwill	31	'	'	'	'	'	'
Amount of tax deductible from goodwill	18	'	'	'	'	'	'
Intangible assets	29	'	24	5	2	'	'
Intangible assets, weighted-average amortization period	'	'	'7 years 2 months 12 days	'3 years	'5 years	'	'
Contingent consideration, minimum	0	'	'	'	'	'	'
Contingent consideration, maximum	25	'	'	'	'	'	'
Contingent consideration, liability	$25	$65	'	'	'	'	'

Goodwill_and_Identifiable_Inta2

Goodwill and Identifiable Intangible Assets - Summary of Changes in Goodwill (Detail) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
Goodwill [Roll Forward]	'
Beginning Balance	$3,573
Goodwill assigned in purchase price allocations	31
Foreign currency translation adjustments and other	-104
Ending Balance	$3,500

Goodwill_and_Identifiable_Inta3

Goodwill and Identifiable Intangible Assets - Schedule of Intangible Assets (Detail) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Finite Lived And Indefinite Lived Intangible Assets [Line Items]	'	'
Gross carrying amount	$3,510	$3,588
Accumulated amortization	-1,245	-1,071
Weighted average amortization period (years)	'10 years 9 months 18 days	'
Databases	'	'
Finite Lived And Indefinite Lived Intangible Assets [Line Items]	'	'
Gross carrying amount	696	725
Accumulated amortization	-628	-549
Weighted average amortization period (years)	'6 months	'
Client Relationships And Other	'	'
Finite Lived And Indefinite Lived Intangible Assets [Line Items]	'	'
Gross carrying amount	2,132	2,152
Accumulated amortization	-580	-491
Weighted average amortization period (years)	'14 years	'
Trade Names (Finite-Lived)	'	'
Finite Lived And Indefinite Lived Intangible Assets [Line Items]	'	'
Gross carrying amount	145	151
Accumulated amortization	-37	-31
Weighted average amortization period (years)	'14 years 1 month 6 days	'
Trade Names (Indefinite-Lived)	'	'
Finite Lived And Indefinite Lived Intangible Assets [Line Items]	'	'
Gross carrying amount	$537	$560

Goodwill_and_Identifiable_Inta4

Goodwill and Identifiable Intangible Assets - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'	'	'	'
Intangible asset amortization expense	$73	$71	$220	$214

Goodwill_and_Identifiable_Inta5

Goodwill and Identifiable Intangible Assets - Schedule of Amortization Expense Associated With Intangible Assets (Detail) (USD $)	Sep. 30, 2014
In Millions, unless otherwise specified
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]	'
Remainder of 2014	$71
2015	176
2016	149
2017	136
2018	133
Thereafter	$1,063

Severance_Impairment_and_Other2

Severance, Impairment and Other Charges - Schedule of Severance Related Reserves (Detail) (Severance, USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
2014 Plan	'
Restructuring Cost And Reserve [Line Items]	'
Charges	$19
Cash payments	-7
Ending balance	12
2013 Plan	'
Restructuring Cost And Reserve [Line Items]	'
Beginning balance	12
Cash payments	-4
Ending balance	8
2012 Plan	'
Restructuring Cost And Reserve [Line Items]	'
Beginning balance	6
Cash payments	-3
Ending balance	$3

Severance_Impairment_and_Other3

Severance, Impairment and Other Charges - Schedule of Severance Related Reserves (Parenthetical) (Detail) (Severance, USD $)	1 Months Ended				3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	31-May-14	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2013
Severance	'	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'	'
Pre-tax severance charge	$4	$15	$12	$23	'
Reversal of restructuring charge	'	'	'	'	$6

Severance_Impairment_and_Other4

Severance, Impairment and Other Charges - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Restructuring And Related Activities [Abstract]	'	'	'	'
Impairment charges	'	$6	$10	$7
Impaired leases for properties	7	'	7	'
Write-down of assets and contract-related charges	'	'	$3	'

Derivatives_and_Fair_Value_Add

Derivatives and Fair Value - Additional Information (Detail)

3 Months Ended

9 Months Ended

3 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

9 Months Ended

9 Months Ended

9 Months Ended

9 Months Ended

In Millions, unless otherwise specified

Sep. 30, 2014

Jun. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Feb. 08, 2013

Feb. 07, 2013

Jun. 30, 2014

Sep. 30, 2014

Mar. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Apr. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

31-May-14

Apr. 30, 2014

31-May-10

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

31-May-10

Sep. 30, 2014

Sep. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

31-May-10

Sep. 30, 2014

Sep. 30, 2014

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Bolivars

Bolivars

SICAD II

SICAD II

Venezuelan Bolivars

Venezuelan Bolivars

Venezuelan Bolivars

Computer software

Fair Value Measurements, Non-recurring

Fair Value Measurements, Non-recurring

Level 2

Level 2

Foreign Exchange Contracts

Foreign Exchange Contracts

Foreign Exchange Contracts

Foreign Exchange Contracts

Foreign Exchange Contracts

Foreign Exchange Contracts

Foreign Exchange Contracts

Interest Rate Cap

Interest Rate Cap

Interest Rate Cap

Interest Rate Cap

Interest Rate Cap

Interest Rate Cap

Interest Rate Cap

Interest Rate Swap

Interest Rate Swap

Interest Rate Swap

Interest Rate Swap

Interest Rate Swap

Minimum

Minimum

Minimum

Minimum

Minimum

Minimum

Maximum

Maximum

Maximum

Maximum

Maximum

Maximum

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Computer software

Lease Impairment

USD ($)

USD ($)

USD ($)

USD ($)

EUR (€)

Designated as Hedging Instrument

Designated as Hedging Instrument

Not Designated as Hedging Instrument

Not Designated as Hedging Instrument

Designated as Hedging Instrument

Designated as Hedging Instrument

Designated as Hedging Instrument

Not Designated as Hedging Instrument

Not Designated as Hedging Instrument

Not Designated as Hedging Instrument

Not Designated as Hedging Instrument

USD ($)

USD ($)

Designated as Hedging Instrument

Not Designated as Hedging Instrument

Not Designated as Hedging Instrument

Country

Interest Rate Cap

Interest Rate Cap

Interest Rate Swap

Interest Rate Swap

Interest Rate Swap

Interest Rate Cap

Interest Rate Cap

Interest Rate Swap

Interest Rate Swap

Interest Rate Swap

Interest Rate Swap

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Interest Rate Caps April Two Thousand Fourteen

Interest Rate Caps April Two Thousand Fourteen

USD ($)

USD ($)

Interest Rate Caps May Two Thousand Ten

Interest Rate Caps May Two Thousand Ten

USD ($)

USD ($)

USD ($)

Designated as Hedging Instrument

Designated as Hedging Instrument

Interest Rate Swap Agreements April 2014

Designated as Hedging Instrument

Designated as Hedging Instrument

Interest Rate Swap Agreements April 2014

Interest Rate Swap Agreements May 2010

USD ($)

USD ($)

Interest Rate Caps April Two Thousand Fourteen

Interest Rate Caps April Two Thousand Fourteen

Interest Rate Caps April Two Thousand Fourteen

Interest Rate Caps April Two Thousand Fourteen

Derivative Instruments And Hedging Activities Disclosures [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of countries in which the company transacts business

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100

'

'

'

'

'

'

'

'

'

'

'

Total debt

$3,899

'

$3,899

'

$4,960

'

'

'

'

'

'

'

'

'

'

'

'

$1,093

$1,093

€ 869

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Foreign exchange gain related to net investment hedge

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

94

105

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative, nominal value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

215

202

228

219

1,000

'

1,000

110

365

'

'

'

'

565

225

375

'

'

'

'

'

'

'

'

'

'

'

'

Strike rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4.00%

'

'

'

'

'

'

'

2.00%

'

'

'

'

3.00%

'

'

'

'

Premiums paid

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

21

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative, maturity year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2015

'

'

'

'

'

'

'

'2017

'

'

'

'2017

'2019

'

'

'

'2021

'2016

Notional amounts, borrowings

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

600

375

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fixed interest payment rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.40%

3.00%

'

'

'

2.10%

3.30%

'

'

Derivative basis spread on variable rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrealized gain (loss) on foreign currency derivatives, net, before tax

17

'

17

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,910

5,280

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Earn-out payment, final settlement

25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Change in fair value of contingent consideration liability

9

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment charge for a leased facility

'

7

7

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment charges of computer software

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value measurement for impaired lease facility

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value measurement for impaired computer software

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Adjustment of currency exchange rate

'

'

'

'

'

6.3

4.3

50

50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Losses on Venezuelan remeasurement

'

'

$49

$14

'

'

'

$49

'

$14

$49

$14

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivatives_and_Fair_Value_Sch

Derivatives and Fair Value - Schedule of Components of Foreign Exchange Gain (Loss) (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'	'	'	'
Translation of non-functional currency debt	'	($34)	'	($22)
Revaluation of other non-functional currency assets and liabilities	8	-17	-48	-14
Effect of derivatives	-4	'	-4	7
Total foreign exchange gain (loss)	$4	($51)	($52)	($29)

Derivatives_and_Fair_Value_Sch1

Derivatives and Fair Value - Schedule of Components of Foreign Exchange Gain (Loss) (Parenthetical) (Detail) (USD $)	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2013	Sep. 30, 2014	Sep. 30, 2013
Derivative Instruments And Hedging Activities Disclosures [Line Items]	'	'	'
Losses on Venezuelan remeasurement	'	$49	$14
Venezuelan Bolivars	'	'	'
Derivative Instruments And Hedging Activities Disclosures [Line Items]	'	'	'
Losses on Venezuelan remeasurement	$14	$49	$14

Derivatives_and_Fair_Value_Sch2

Derivatives and Fair Value - Schedule of Fair Value of Derivative Instruments (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Derivative Instruments And Hedging Activities Disclosures [Line Items]	'	'
Derivatives assets	$33	$9
Derivatives liabilities	23	27
Designated as Hedging Instrument | Foreign Exchange Contracts	'	'
Derivative Instruments And Hedging Activities Disclosures [Line Items]	'	'
Derivative, nominal value	215	202
Designated as Hedging Instrument | Foreign Exchange Contracts | Accounts receivable	'	'
Derivative Instruments And Hedging Activities Disclosures [Line Items]	'	'
Derivatives assets	13	6
Designated as Hedging Instrument | Foreign Exchange Contracts | Accounts payable	'	'
Derivative Instruments And Hedging Activities Disclosures [Line Items]	'	'
Derivatives liabilities	'	4
Designated as Hedging Instrument | Interest Rate Cap	'	'
Derivative Instruments And Hedging Activities Disclosures [Line Items]	'	'
Derivative, nominal value	1,000	'
Designated as Hedging Instrument | Interest Rate Cap | Non-Current Assets	'	'
Derivative Instruments And Hedging Activities Disclosures [Line Items]	'	'
Derivatives assets	16	'
Designated as Hedging Instrument | Interest Rate Swap	'	'
Derivative Instruments And Hedging Activities Disclosures [Line Items]	'	'
Derivatives liabilities	10	'
Derivative, nominal value	565	'
Not Designated as Hedging Instrument | Foreign Exchange Contracts	'	'
Derivative Instruments And Hedging Activities Disclosures [Line Items]	'	'
Derivative, nominal value	228	219
Not Designated as Hedging Instrument | Foreign Exchange Contracts | Accounts receivable	'	'
Derivative Instruments And Hedging Activities Disclosures [Line Items]	'	'
Derivatives assets	4	3
Not Designated as Hedging Instrument | Foreign Exchange Contracts | Accounts payable	'	'
Derivative Instruments And Hedging Activities Disclosures [Line Items]	'	'
Derivatives liabilities	7	11
Not Designated as Hedging Instrument | Interest Rate Cap	'	'
Derivative Instruments And Hedging Activities Disclosures [Line Items]	'	'
Derivative, nominal value	110	365
Not Designated as Hedging Instrument | Interest Rate Swap	'	'
Derivative Instruments And Hedging Activities Disclosures [Line Items]	'	'
Derivatives liabilities	6	12
Derivative, nominal value	$225	$375

Derivatives_and_Fair_Value_Sch3

Derivatives and Fair Value - Schedule of Fair Value of Derivative Instruments (Parenthetical) (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Derivative Instruments And Hedging Activities Disclosures [Line Items]	'	'
Accrued and other current liabilities	$475	$583
Other liabilities	73	111
Interest Rate Swap	'	'
Derivative Instruments And Hedging Activities Disclosures [Line Items]	'	'
Accrued and other current liabilities	2	'
Other liabilities	$14	$12

Derivatives_and_Fair_Value_Sch4

Derivatives and Fair Value - Schedule of Effect of Derivatives on Financial Performance (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Other Income (Loss), Net	'	'	'	'
Derivative Instruments And Hedging Activities Disclosures [Line Items]	'	'	'	'
Amount of Income/(Loss) Reclassified from AOCI into Earnings	$1	$4	$1	$11
Interest Expense	'	'	'	'
Derivative Instruments And Hedging Activities Disclosures [Line Items]	'	'	'	'
Amount of Income/(Loss) Reclassified from AOCI into Earnings	-2	'	-2	'
Foreign Exchange Contracts	'	'	'	'
Derivative Instruments And Hedging Activities Disclosures [Line Items]	'	'	'	'
Amount of Income/(Loss) Recognized in AOCI	15	-5	12	9
Interest Rate Derivatives	'	'	'	'
Derivative Instruments And Hedging Activities Disclosures [Line Items]	'	'	'	'
Amount of Income/(Loss) Recognized in AOCI	($3)	'	($16)	'

Derivatives_and_Fair_Value_Sch5

Derivatives and Fair Value - Schedule of Pre-Tax Gain (Loss) Recognized in Earnings on Derivatives Not Designated as Hedging Instruments (Detail) (Not Designated as Hedging Instrument, USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Derivative Instruments And Hedging Activities Disclosures [Line Items]	'	'	'	'
Total derivatives not designated as hedging instruments	($5)	($2)	($5)	$3
Foreign Exchange Contracts	'	'	'	'
Derivative Instruments And Hedging Activities Disclosures [Line Items]	'	'	'	'
Total derivatives not designated as hedging instruments	-5	-4	-5	-4
Interest Rate Derivatives	'	'	'	'
Derivative Instruments And Hedging Activities Disclosures [Line Items]	'	'	'	'
Total derivatives not designated as hedging instruments	'	$2	'	$7

Derivatives_and_Fair_Value_Sch6

Derivatives and Fair Value - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Assets	'	'
Derivatives assets	$33	$9
Liabilities	'	'
Contingent consideration, liability	25	65
Derivatives liabilities	23	27
Level 3	'	'
Liabilities	'	'
Contingent consideration, liability	25	65
Fair value measurements, recurring basis	'	'
Assets	'	'
Short-term investments	1	4
Derivatives assets	33	9
Total assets	34	13
Liabilities	'	'
Contingent consideration, liability	25	65
Derivatives liabilities	23	27
Total liabilities	48	92
Fair value measurements, recurring basis | Level 2	'	'
Assets	'	'
Short-term investments	1	4
Derivatives assets	33	9
Total assets	34	13
Liabilities	'	'
Derivatives liabilities	23	27
Total liabilities	23	27
Fair value measurements, recurring basis | Level 3	'	'
Liabilities	'	'
Contingent consideration, liability	25	65
Total liabilities	$25	$65

Derivatives_and_Fair_Value_Sch7

Derivatives and Fair Value - Schedule of Level 3 Acquisition-Related Contingent Consideration Liabilities Carried at Fair Value on a Recurring Basis (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014
			Level 3
Business Acquisition Contingent Consideration [Line Items]	'	'	'
Beginning balance	'	$65	$65
New acquisitions	'	'	3
Cash payments	-25	'	-28
Changes in fair value estimates included in Selling and administrative expenses	-9	'	-15
Ending balance	$25	$65	$25

Debt_Schedule_of_Debt_Detail

Debt - Schedule of Debt (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Debt Instrument [Line Items]	'	'
Principal Amount of Debt	$3,923	$5,027
Less: Unamortized Discounts	-24	-67
Total Debt	3,899	4,960
12.5% Senior Notes due 2018	'	'
Debt Instrument [Line Items]	'	'
Principal Amount of Debt	'	1,000
7.375%/8.125% Senior PIK Toggle Notes due 2018	'	'
Debt Instrument [Line Items]	'	'
Principal Amount of Debt	'	750
6.00% Senior Notes due 2020	'	'
Debt Instrument [Line Items]	'	'
Principal Amount of Debt	500	500
USD LIBOR | Senior Secured Term A Loan due 2019	'	'
Debt Instrument [Line Items]	'	'
Principal Amount of Debt	311	'
USD LIBOR | Senior Secured Term B Loan due 2021	'	'
Debt Instrument [Line Items]	'	'
Principal Amount of Debt	1,739	1,747
USD LIBOR | Revolving Credit Facility due 2019	'	'
Debt Instrument [Line Items]	'	'
Principal Amount of Debt	272	'
EUR LIBOR | Senior Secured Term A Loan due 2019	'	'
Debt Instrument [Line Items]	'	'
Principal Amount of Debt	166	'
EUR LIBOR | Senior Secured Term B Loan due 2021	'	'
Debt Instrument [Line Items]	'	'
Principal Amount of Debt	$935	$1,030

Debt_Schedule_of_Debt_Parenthe

Debt - Schedule of Debt (Parenthetical) (Detail)	9 Months Ended
	Sep. 30, 2014
12.5% Senior Notes due 2018	'
Debt Instrument [Line Items]	'
Debt instrument, interest rate	12.50%
Debt instrument, maturity year	'2018
7.375%/8.125% Senior PIK Toggle Notes due 2018	'
Debt Instrument [Line Items]	'
Debt instrument, maturity year	'2018
6.00% Senior Notes due 2020	'
Debt Instrument [Line Items]	'
Debt instrument, interest rate	6.00%
Debt instrument, maturity year	'2020
Debt Instrument Cash Interest Rate | 7.375%/8.125% Senior PIK Toggle Notes due 2018	'
Debt Instrument [Line Items]	'
Debt instrument, interest rate	7.38%
Debt Instrument Paid In Kind Rate | 7.375%/8.125% Senior PIK Toggle Notes due 2018	'
Debt Instrument [Line Items]	'
Debt instrument, interest rate	8.13%
USD LIBOR | Senior Secured Term A Loan due 2019	'
Debt Instrument [Line Items]	'
Debt instrument, average floating rate	2.48%
Debt instrument, maturity year	'2019
USD LIBOR | Senior Secured Term B Loan due 2021	'
Debt Instrument [Line Items]	'
Debt instrument, average floating rate	3.50%
Debt instrument, maturity year	'2021
USD LIBOR | Revolving Credit Facility due 2019	'
Debt Instrument [Line Items]	'
Debt instrument, average floating rate	2.40%
Debt instrument, maturity year	'2019
EUR LIBOR | Senior Secured Term A Loan due 2019	'
Debt Instrument [Line Items]	'
Debt instrument, average floating rate	2.31%
Debt instrument, maturity year	'2019
EUR LIBOR | Senior Secured Term B Loan due 2021	'
Debt Instrument [Line Items]	'
Debt instrument, average floating rate	3.75%
Debt instrument, maturity year	'2021

Debt_Schedule_of_Maturities_of

Debt - Schedule of Maturities of Long-Term Debt (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Long Term Debt By Maturity [Abstract]	'	'
Scheduled principal payments, 2014	$13	'
Scheduled principal payments, 2015	51	'
Scheduled principal payments, 2016	51	'
Scheduled principal payments, 2017	57	'
Scheduled principal payments, 2018	69	'
Scheduled principal payments, Thereafter	3,682	'
Total	$3,923	$5,027

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Mar. 31, 2014

Sep. 30, 2014

Sep. 30, 2014

Feb. 28, 2013

Sep. 30, 2013

Oct. 31, 2012

Apr. 30, 2014

Feb. 28, 2010

Jun. 30, 2014

Sep. 30, 2014

Feb. 28, 2010

Apr. 30, 2014

Aug. 31, 2013

Jun. 30, 2014

Sep. 30, 2014

Mar. 31, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Mar. 31, 2014

Sep. 30, 2014

Sep. 30, 2014

Mar. 31, 2014

Sep. 30, 2014

Sep. 30, 2014

Minimum

Maximum

Term Loan Amendment

Term Loan Amendment

Recapitalization

12.5% Senior Notes due 2018

12.5% Senior Notes due 2018

12.5% Senior Notes due 2018

12.5% Senior Notes due 2018

6.00% Senior Notes due 2020

7.375%/8.125% Senior PIK Toggle Notes due 2018

7.375%/8.125% Senior PIK Toggle Notes due 2018

7.375%/8.125% Senior PIK Toggle Notes due 2018

7.375%/8.125% Senior PIK Toggle Notes due 2018

2014 Term Loan Amended

2014 Term Loan Amended

Senior Secured Term A Loan due 2019

Senior Secured Term A Loan due 2019

Senior Secured Term A Loan due 2019

Senior Secured Term A Loan due 2019

Senior Secured Term B Loan due 2021

Senior Secured Term B Loan due 2021

Senior Secured Term B Loan due 2021

Revolving Credit Facility

Revolving Credit Facility

Minimum

Maximum

2014 Term Loan Amended

2014 Term Loan Amended

2014 Term Loan Amended

2014 Term Loan Amended

2014 Term Loan Amended

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

New term loans commitments

'

'

'

'

'

$500,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$228,000,000

'

Line of credit facility, borrowing capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000,000

'

'

500,000,000

500,000,000

'

Reduced LIBOR floor on tranches of debt, basis points

'

'

'

'

'

'

'

'

0.25%

'

'

'

'

'

'

'

'

'

'

'

0.25%

'

'

'

'

'

'

'

'

'

'

Debt extinguishment losses

'

'

-79,000,000

-9,000,000

'

'

'

'

'

-9,000,000

'

'

'

-189,000,000

'

'

'

'

-30,000,000

'

'

-11,000,000

'

'

'

'

'

'

'

'

'

Third party fees in other income (loss), net

'

'

'

'

'

'

'

'

'

3,000,000

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

Debt instrument maturity date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2019-03

'

'

'2021-03

'

'

'2019-03

Reduced borrowing margins on tranches of debt, basis points

'

'

'

'

'

'

'

'

0.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Extended maturity date of Revolving Credit Facility

'

'

'

'

'

'

'

'

'

'

'2017-08

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Scheduled principal payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.25%

2.50%

'

'

0.25%

'

'

'

'

Line of credit facility, unused capacity, commitment fee percentage

'

'

'

'

'

'

0.30%

0.40%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, principal amount

'

'

'

'

'

'

'

'

'

'

'

1,000,000,000

1,000,000,000

'

'

500,000,000

750,000,000

750,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, maturity year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2018

'2020

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of exchange of 2018 notes

'

'

'

'

'

'

'

'

'

'

'

'

99.96%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, interest rate

'

'

'

'

'

'

'

'

'

'

'

'

12.50%

'

'

6.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of principal amount redeemed

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash paid for accrued interest on debt

'

'

'

'

'

'

'

'

'

'

'

17,000,000

'

'

'

'

6,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, make whole premium

'

'

'

'

'

'

'

'

'

'

'

136,000,000

'

'

'

'

15,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Write-off of debt issuance costs and discounts

'

'

'

'

'

'

'

'

'

'

'

'

'

53,000,000

'

'

'

'

15,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, no call redemption period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt maturity date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1-Sep-18

'

'

'

'

'

'

'

'

'

'

'

Dividends paid to shareholders

'

'

'

'

745,000,000

'

'

'

'

'

'

'

'

'

'

'

'

753,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Payment of transaction fees and expenses

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

17,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument interest payment commencing date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1-Mar-14

'

'

'

'

'

'

'

'

'

'

'

Debt instrument frequency of interest payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Interest was to be paid semi-annually in March and September of each year, commencing March 1, 2014.

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, unamortized discount

24,000,000

'

24,000,000

'

67,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fees and expenses related to issuance

59,000,000

'

59,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest expense, amortization of fees and expenses related to debt issuance

$3,000,000

$9,000,000

$15,000,000

$27,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Pension_and_Postretirement_Ben2

Pension and Postretirement Benefits - Components of Net Periodic Benefit Cost (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
U.S. Plans Pension Benefits	'	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'	'
Service cost	$2	$2	$7	$8
Interest cost	3	3	9	7
Expected return on plan assets	-5	-5	-15	-14
Amortization of net loss	'	1	'	1
Net periodic benefit cost	'	1	1	2
Non-U.S. Plans Pension Benefits	'	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'	'
Service cost	1	2	4	4
Interest cost	3	2	8	7
Expected return on plan assets	-3	-3	-9	-8
Net periodic benefit cost	$1	$1	$3	$3

Pension_and_Postretirement_Ben3

Pension and Postretirement Benefits - Additional Information (Detail) (Other Benefits, USD $)	9 Months Ended		3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
			Maximum	Maximum
Defined Benefit Plan Disclosure [Line Items]	'	'	'	'
Post-retirement benefit (credit) cost	($1)	$1	($1)	$1
Contribution made to plans	18	'	'	'
Expected contribution of remaining period	$2	'	'	'

Shareholders_Equity_Additional

Shareholders' Equity - Additional Information (Detail) (USD $)	0 Months Ended
	Mar. 24, 2014	Sep. 30, 2014	Apr. 09, 2014	Dec. 31, 2013
Shareholders Equity [Line Items]	'	'	'	'
Shareholders' equity, reverse stock split	'The Company effected a 10-to-1 reverse stock split of its common stock. In connection with the split, the par value of the Company’s common stock changed from $0.001 per share to $0.01 per share.	'	'	'
Common stock, par value	$0.00	$0.01	'	$0.01
Preferred stock, shares authorized	'	'	50,000,000	'
Preferred stock, par value	'	'	$0.01	'
Common Stock, shares authorized	'	700,000,000	'	307,500,000
Reverse Stock Split	'	'	'	'
Shareholders Equity [Line Items]	'	'	'	'
Common stock, par value	$0.01	'	'	'

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	Aug. 31, 2013	Sep. 30, 2014	Aug. 31, 2013	Sep. 30, 2014	Sep. 30, 2014	Aug. 31, 2013
		Stock Options	Stock Options	Phantom SARs	Restricted Stock Units	Unvested Options
			2010 Equity Plan			2010 Equity Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'	'	'
Stock options, exercise price	'	$19.50	'	'	'	'
Stock options, vesting period	'	'5 years	'	'	'	'
Stock options, shares granted	'	135,000	'	'	'	'
Stock units granted	'	'	'	15,000	1,442,000	'
Stock appreciation rights, exercise price	'	'	'	$19.50	'	'
Restricted stock units, vested percentage	'	'	'	'	50.00%	'
Divided declared, per share	$2.60	'	$2.60	'	'	'
Reduction in exercise price	'	'	'	'	'	($2.60)

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended		3 Months Ended	6 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2013	Jun. 30, 2014	Sep. 30, 2013	Sep. 30, 2014
					Conclusion of US Federal Income Tax Examination	Conclusion of US Federal Income Tax Examination	Conclusion of US Federal Income Tax Examination	Minimum
								Country
Income Tax [Line Items]	'	'	'	'	'	'	'	'
Number of countries in which the company transacts business	'	'	'	'	'	'	'	100
(Provision for) benefit from income taxes	($11)	$20	$141	$6	$10	$6	$10	'
Effective tax rate	20.40%	50.50%	41.60%	97.00%	'	'	'	'
Unrecognized tax benefits, interest and penalties	'	'	2	2	'	'	'	'
Tax expense related to unrecognized tax benefits	5	4	5	4	'	'	'	'
Unrecognized tax benefits to be recognized over the next 12 months	$2	'	$2	'	'	'	'	'

Contingencies_Additional_Infor

Contingencies - Additional Information (Detail) (SKI Contingency, USD $)	9 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2010	Dec. 31, 2008
SKI Contingency	'	'	'
Loss Contingencies [Line Items]	'	'	'
Contingency reserve	'	'	$4
Additional contingency reserve	'	2	'
GSA settlement amount	$1.50	'	'

Related_Party_Additional_Infor

Related Party - Additional Information (Detail) (Management Services Agreement, USD $)	3 Months Ended			9 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Mar. 31, 2014	Sep. 30, 2013	Sep. 30, 2013
Management Services Agreement	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'
Related party transaction, settlement amount	$72	'	'	'
Management fees paid for provision of services	'	$2	$2	$6

Related_Party_Summary_of_Activ

Related Party - Summary of Activity with Sponsors (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Related Party Transactions [Abstract]	'	'	'	'
Related party transactions, proceeds from sale of offerings	$1	$2	$5	$7
Related party transactions, purchase of goods and services	($1)	($2)	($5)	($4)

Operations_by_Business_Segment2

Operations by Business Segment - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2014
	Segment
Segment Reporting Information [Line Items]	'
Number of operating segments	1
Number of reportable segments	1
Minimum	'
Segment Reporting Information [Line Items]	'
Number of countries in which the company operates	100

Operations_by_Business_Segment3

Operations by Business Segment - Schedule of Geographic Information for Operating Regions (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Geographical Information [Line Items]	'	'	'	'
Revenue	$656	$633	$1,963	$1,870
Operating income (loss)	93	100	121	276
Americas	'	'	'	'
Geographical Information [Line Items]	'	'	'	'
Revenue	303	294	887	851
Operating income (loss)	71	78	204	224
EMEA	'	'	'	'
Geographical Information [Line Items]	'	'	'	'
Revenue	240	227	739	682
Operating income (loss)	57	58	183	176
Asia Pacific	'	'	'	'
Geographical Information [Line Items]	'	'	'	'
Revenue	113	112	337	337
Operating income (loss)	35	39	103	117
Corporate and Other	'	'	'	'
Geographical Information [Line Items]	'	'	'	'
Operating income (loss)	($70)	($75)	($369)	($241)

Operations_by_Business_Segment4

Operations by Business Segment - Schedule of Geographic Information for Operating Regions (Parenthetical) (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Geographical Information [Line Items]	'	'	'	'
Revenue	$656	$633	$1,963	$1,870
Depreciation and amortization related to purchase accounting adjustments	109	98	331	303
United States	'	'	'	'
Geographical Information [Line Items]	'	'	'	'
Revenue	249	233	718	682
Japan	'	'	'	'
Geographical Information [Line Items]	'	'	'	'
Revenue	63	66	193	200
Americas	'	'	'	'
Geographical Information [Line Items]	'	'	'	'
Revenue	303	294	887	851
Depreciation and amortization related to purchase accounting adjustments	31	31	94	94
EMEA	'	'	'	'
Geographical Information [Line Items]	'	'	'	'
Revenue	240	227	739	682
Depreciation and amortization related to purchase accounting adjustments	21	22	66	65
Asia Pacific	'	'	'	'
Geographical Information [Line Items]	'	'	'	'
Revenue	113	112	337	337
Depreciation and amortization related to purchase accounting adjustments	$10	$10	$30	$32

Earnings_per_Share_Composition

Earnings per Share - Composition of Basic and Diluted Weighted Average Shares Outstanding (Detail)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share [Abstract]	'	'	'	'
Basic weighted-average common shares outstanding	332.1	280	314.1	280
Effect of dilutive stock-based awards	10.2	0	0	0
Diluted weighted-average common shares outstanding	342.3	280	314.1	280
Shares excluded from computation of diluted earnings (loss) per share:	'	'	'	'
Weighted average potential common shares excluded from computation due to anti-dilutive effect	0	18.9	19.1	18.9